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Chapter 1  Introduction and objectives 
1 Introduction and objectives 
 
Cancer is a major public health problem in the world, causing millions of people 
to die every year. In fact, one in four deaths in the United States is due to cancer [1]. 
Cancer detected at an early stage, before it has metastasized, can often be treated 
successfully by surgery or local irradiation. In contrast, cancer diagnosed after it has 
developed metastases, treatments are much less successful and in most cases only 
palliative. Metastases, rather than primary tumors, are responsible for most cancer 
deaths. Therefore, improved ways of early detection of metastatic disease are urgently 
being sought. Development of biochemical markers, which are measurable in blood, 
easy repeatable, inexpensive, and safe for patients, is a promising strategy to improve 
the diagnosis of metastasis. Biochemical markers providing a clinician with both 
accurate diagnostic and prognostic information regarding cancer patients are most 
desirable. Prognostic value of biochemical markers will assist in identifying patients at 
risk in order to provide them with timely and appropriate treatment. Such stratification of 
patients into risk groups based on levels of biochemical markers will also enable 
clinicians to use diagnostic recourses such as radiography and scintigraphy more cost-
effectively. 
Recently there has been a focus of attention towards bone markers, which reflect 
subtle changes in bone metabolism like bone formation and resorption. In fact, once a 
tumor invades the bone it disturbs finely balanced processes of bone formation and 
resorption. These changes in bone metabolism can easily be assessed using bone 
markers in blood [2]. These markers are particularly useful to detect bone metastases 
from cancers, which preferentially metastasize to bone, such as prostate cancer (PCa) 
and breast cancer. Renal cell carcinoma (RCC) is also known to metastasize frequently 
to the bone. However, at present there is no ideal test for detecting bone metastases 
and there is still much room for the improvement of the diagnosis of bone metastases. 
In the course of searching for a better and more reliable marker for cancer 
metastases, osteopontin (OPN) was examined in this study. OPN, a glycoprotein, was 
recently identified as a key protein in tumor genesis and progression [3]. OPN exists in 
a secreted form in all body fluids that makes it available for routine determinations in 
blood [4]. In addition, OPN is abundantly distributed in bone tissue and involved in the 
regulation of bone turnover [5-7]. This indicates that plasma OPN could provide 
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diagnostic information relating to skeletal metastases. Therefore, this study was 
undertaken to evaluate the clinical usefulness of plasma OPN in two urologic cancers: 
PCa and RCC with all patients classified into subgroups with distant bone and non-bone 
metastases, with metastases in regional lymph nodes, and organ-confined disease. Its 
diagnostic and prognostic performance was validated against the established markers 
for bone metastases such as bone formation markers: N-terminal propeptide of type I 
procollagen (PINP), bone-specific alkaline phosphatase (bALP), and bone resorption 
marker: cross-linked carboxyterminal telopeptide of type I collagen (ICTP). 
This chapter functions as an introduction of the thesis and outlines statistical 
figures on PCa, RCC and their metastases. Furthermore, it describes aforementioned 
bone markers as well as structure and functions of OPN. The formulation of the 
objectives of the current study will conclude this chapter. 
 
1.1 Prostate cancer and metastases 
 
PCa is the most common malignancy to afflict elderly men. In 2006, PCa is 
estimated to cause 234,460 new cases and 27,350 deaths in the USA [1]. While most of 
the patients with organ-confined tumors can be curatively treated by radical 
prostatectomy, about 20% of patients experience tumor recurrence or metastatic tumor 
progression. The distinct predilection site of hematogenous spread of PCa is bone. 
Bone lesions from prostate cancer are characterized by increased osteoblastic reaction 
[8]. Bone metastases in PCa patients are associated with pain, impaired mobility, 
pathological fracture, spinal or nerve root compression, and bone marrow infiltration. Up 
to 70% of patients with advanced PCa have bone metastases, which significantly 
reduce quality of life and cause morbidity [9,10]. More than 85% of those patients who 
die of PCa have bone metastases [11]. The survival of patients is essentially 
determined by the extent of metastatic spread within the skeletal system [12]. These 
few figures underline the great challenge to detect bone metastases at an early stage or 
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1.2 Renal cell carcinoma and metastases 
 
In 2006, RCC is estimated to cause 38,890 new cases and 12,840 deaths in the 
USA [1]. RCC is, most of the times, clinically asymptomatic and casually detected by 
routine ultrasonographic follow-up in persons otherwise in inconspicuous conditions 
[13]. However, at the time of initial presentation, about 50% patients have localized 
carcinoma, while 20% suffer from regional and another 20% from distant metastases 
[14]. Distant metastases most frequently occur in the lungs, bone, liver or brain. Bone 
metastases are found in 30% of patients with metastases either alone or in combination 
with metastases in other locations [15-17]. In contrast to PCa skeletal metastases from 
RCC are osteolytic [18]. Metastatic spread to bones accounts for high morbidity in these 
patients and is a poor survival factor [19,20]. These data indicate the importance of 
early detection of metastases in RCC patients. 
In relation to histological types of RCC clear cell RCC is the most frequent one 
with an incidence of 70% followed by papillary and chromophobe types with an 
incidence of 10% and 5%, respectively. Histological feature of RCC provides prognostic 
information regarding tumor patients. Clear cell type has a worse prognosis for RCC 
patients compared to both papillary and chromophobe types [21]. In a recent study, a 5-
year survival of patients with clear cell and chromophobe RCC types was 50% and 
78%, respectively [22]. 
 
1.3 Bone markers as bone metabolic indicators 
 
Although bone seems to be an inert tissue, in fact, it is a metabolically active one, 
which continuously undergoes turnover that consists of bone resorption and formation 
processes [23]. Bone markers are mainly represented by bone cell enzymes such as 
bALP or by-products liberated during synthesis and degradation of type I collagen such 
as PINP and ICTP. As mentioned earlier, bone markers bALP, PINP, and ICTP were 
used in this study to validate the diagnostic and prognostic significance of OPN. 
Therefore, in order to outline the origin of the above-mentioned bone markers, bone 
turnover and metabolism of type I collagen are described in this section. In addition, it 
also gives a short overview of the clinical utility of these bone markers in human 
malignancies. 
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1.3.1 Bone turnover 
 
Bone tissue consists of three components: an organic matrix, or osteoid, bone 
mineral, and bone cells [24]. The cells responsible for resorption and formation are 
osteoclasts and osteoblasts, respectively. Under the physiological conditions, bone 
resorption takes approximately 10 days, which is then followed by formation that lasts 
for up to 3 months. These two processes are tightly coupled through well-coordinated 
mechanisms [23,25]. 
 
Figure 1. Bone turnover. Reproduced with permission 
from M. J. Seibel ref [25]. 
 
As shown in Figure 1, first, (a) osteoclasts should anchor to the bone matrix, 
which is mediated by an ariginine-glycine-asparic acid (RGD) cell-binding sequence of 
extracellular matrix (ECM) proteins such as OPN [6]. Osteoclasts dissolve bone mineral 
by massive acid secretion and also secrete specialized proteinases such as matrix 
metalloproteinases (MMPs) and cathepsin K that degrade the organic matrix, mainly 
type I collagen [26,27]. The resorption process takes place in an extracellular 
compartment covered by the ruffled border of the osteoclast and results in formation of 
the resorption pit [27]. (b) After the erosion of a cavity is completed by osteoclasts, 
osteoblasts fill the cavity with an equivalent amount of organic matrix. (c) Newly formed 
osteoid undergoes mineralization with hydroxyapatite and (d) the remodelled area then 
passes into a quiescent phase before a new cycle begins [28]. 
Therefore, this continuous process of bone turnover plays an important role in 
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1.3.2 Bone-specific alkaline phosphatase 
 
bALP is an enzyme synthesized by the osteoblasts in extremely high amounts 
during bone formation. Due to this fact bALP is considered as a reliable indicator of 
bone formation activity [28]. Total alkaline phosphatase (tALP) has been used widely as 
a marker of bone formation and is mainly composed of hepatic, renal, and bone 
isoenzymes. However, its diagnostic value is restricted since the bone isoform 
contributes to only about 40% of the total activity [23]. Therefore, measurement of bALP 
could be more accurate in the assessment of bone formation [29]. 
 
1.3.3 Propeptides and telopeptides of type I collagen 
 
Type I collagen makes up 90% of bone matrix and the remaining 10% include 
proteins such as osteocalcin, osteonectin, and OPN [24]. Although type I collagen is 
found in connective tissue and some other tissues, bone has a distinctly higher 
proportion and turnover of this protein [28]. During the bone formation the osteoblast 
secretes into the extracellular space the type I procollagen molecules which form triple 
helixes each consisting of two chains of α1 and one chain of α2 procollagen [30]. N- and 
C-terminal portions of these triple helix molecules are cleaved by proteinases, which 
results in releasing two propeptides PINP and PICP (Figure 2). This cleavage allows 
molecules to aggregate into mature collagen fibrils by forming terminal cross-links 
[30,31]. Therefore, the cleaved by-products, PINP and PICP, directly reflect the rate of 
synthesis of type I collagen and thus of bone formation. 
 
Figure 2. Schematic structure of collagen type I molecule. Reproduced 
with permission from Dr. S Robins, Aberdeen, Scotland. 
 
In contrast, during bone resorption type I collagen undergoes degradation in 
which the collagen molecule is cleaved at both C- and N-terminal ends. This generates 
N- and C-telopeptides that reflect the rate of type I collagen degradation and thus of 
bone resorption. It is of interest that two different fragments are being generated on 
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each telopeptide end. This is due to the existence of different collagenolytic pathways. 
Indeed, ICTP collagen fragments are commonly produced by MMPs while cleavage by 
cathepsin K generates cross-linked carboxyterminal telopeptide of type I collagen 
fragments (CTX) [32,33]. As shown in Figure 3, CTX is a linear eight amino acid 
sequence of alfa1 chain, whereas ICTP, a cross-link-containing collagen peptide, is a 
larger fragment compared to CTX [32]. 
 
Figure 3. ICTP and CTX fragments of collagen I type molecule. 
Reproduced with permission from Dr S Robins, 
Aberdeen, Scotland. (with some modifications). 
 
1.3.4 Clinical utility of bone markers in human malignancies 
 
Metastatic spread of the tumor to bone alters these finely balanced processes of 
bone resorption and formation [2]. Skeletal metastases from PCa accelerate the bone 
formation rate and therefore are called osteoblastic [8]. In contrast, bone metastases 
from RCC are known to increase the rate of bone resorption and are termed osteolytic 
metastases [18]. These changes in bone metabolism caused by metastasis can be 
assessed by evaluating bone markers in blood. In this respect, Koizumi et al. [34] 
showed that PINP and bALP were effective markers in the detection of bone 
metastases in PCa patients and, moreover, PINP was reported as a more accurate 
diagnostic marker than bALP. This was also confirmed in another study, in which serum 
PINP in distinguishing PCa with bone metastases had a sensitivity and specificity of 
100% and 87% compared to 90% and 82 % of bALP [35]. De la Piedra et al. [36] 
showed that serum PINP is an excellent marker for bone metastatic disease from PCa 
with a sensitivity and specificity of 100%. ICTP, a bone resorption marker, was also 
reported to be significantly elevated in PCa patients with bone metastases compared to 
those without bone metastases and BPH patients [34,37]. Moreover, all these markers: 
bALP, PINP, and ICTP correlate closely with Soloway’s grading for bone scans 
reflecting the metastatic burden in PCa patients [37-39]. Besides PCa, in breast, lung, 
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and other malignancies ICTP and tALP were also useful in distinguishing patients with 
bone involvement and associated with the number of metastatic lesions in bone. In that 
study the overall specificity of these two markers was over 90% [40]. 
Bone markers were shown to be helpful in monitoring the response to hormonal 
therapy in PCa patients. In PCa patients with bone metastases, serum ICTP levels 
showed a downward trend along with a clinical response to hormonal treatment, and a 
significant decrease was observed after 12 weeks of treatment [37]. Yoshida et al. 
reported on an earlier response of ICTP levels to hormonal therapy in PCa patients after 
8 weeks of initiation of treatment [39]. Bone markers also provide useful information in 
patients with bone metastases treated with bisphosphonates [41]. 
Bone markers may also be valuable in determining the prognosis in cancer 
patients. A recent study involving 153 metastatic PCa patients showed that the 
increased concentrations of PINP and bALP were strongly associated with shorter 
survival in those patients [38]. Prognostic significance of bALP and PINP related to 
survival in PCa patients was also confirmed in a large study involving 10 bone markers 
[42]. 
 Therefore, bone markers are useful in the evaluation of cancer patients (i) to 
diagnose skeletal metastases, (ii) to assess their response to therapy, and (iii) to 




This section is meant to outline the results of the literature review carried out from 
PubMed concerning OPN and cancer. Furthermore it describes the structure and 
functions of OPN with particular stress on its implications in tumor progression and 
metastasis. 
 
1.4.1 Literature review 
 
OPN is a phosphorylated acidic glycoprotein with RGD sequence that interacts 
with cell surface integrin receptors and promotes cell adhesion, migration, and 
proliferation as well as cell survival. OPN exists as an immobilized ECM molecule in 
mineralized tissues and as a cytokine in body fluids. In bone tissue OPN is the most 
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abundant non-collagenous protein. Due to its multidomain structure OPN plays an 
important role in diverse physiological and pathological processes [4,7,43]. 
Senger et al. [44] first described the protein in 1979 as a marker of transformation 
of epithelial cells indicating its function in tumor biology. Later this protein was identified 
as a key non-collagenous protein in bone matrix and the name “osteopontin” was 
proposed to denote that it is a product of bone cells and that it can form bridge (“pons” 
is Latin for bridge) between cells and the mineral matrix [45]. However, the protein has 
also been shown to be important in various processes such as angiogenesis, wound 
healing and in inflammatory and immune response [4]. It was also named as an early T-
lymphocyte activation 1 protein (Eta-1) in order to emphasize its importance in immune 
activity and bacterial resistance [46]. More than two and a half decades have passed 
since it was first described as a transformation-associated protein. However, there is 
still a considerable interest in the role of OPN in genesis and progression of human 
tumor. 
In order to examine this tendency a PubMed search was performed using the 
keywords “osteopontin” and “cancer”, which retrieved 513 publications with the 
distribution in regard to the date of issue (Figure 4). The current literature review 
suggests that the number of publications involving OPN and cancer has been constantly 













 1987-1990 1991-1994 1995-1998 1999-2002 2003-2006 
Year 
Figure 4. Medical literature review in PubMed on-line library specified by the 
following key words: “osteopontin” and “cancer” (August 2006). 
 
Numerous studies in vitro and in animal models have clearly indicated that OPN 
can function to regulate tumor growth and metastatic spread. Studies on OPN tissue 
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expression have shown that OPN is elevated in a number of tumors compared to 
normal specimens. Moreover, intensity of OPN expression appears to correlate with 
patients’ survival and clinico-pathological data [47-49]. Recent studies involving OPN-
deficient mice [50,51] and techniques using OPN gene transfection [52] have 
considerably contributed to understanding the role of OPN in tumor invasion and 
metastasis. 
Since the main objective of the current study was to investigate the full clinical 
potential of plasma OPN in patients with PCa and RCC, a more focused review of 
previously published findings involving plasma OPN in different malignancies was 
necessary. For this purpose a literature search was carried out from PubMed using the 
keywords “plasma osteopontin” and “cancer”. Each subject-related publication was 
studied and used to construct Table 1, which gives an overview of the results of all 
presently available studies on plasma OPN in different human tumors. 
Table 1. Summary of plasma OPN level in different human cancers: the association 
with clinico-pathological factors of patients and prognostic usefulness 
(August 2006) 
 












































































Prostate [53,54]    +    +++ +++  
Breast [53,55,56] +++ +++   +   +++ +++  
Lung [53,57] ++     +     
Bladder [58] + +    +     
Liver [59,60] +++  ++   + + +++ +++ + 
Multiple myeloma [61,62] +++     +     
Ovarian [63-66] +++     +    +++2
Pancreatic [67] +++          
Uveal [68] +++ +++         
Head and neck [69-71] ++  +   +  ++ +  
Key: P value: +, <0.05; ++, <0.01; +++, <0.001. 
1Compared to controls or/and respective benign disease. 
2Only in combination with other established markers. 
3Evaluated by Kaplan-Meier analysis. 
4Evaluated by Cox regression model. 
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As shown in Table 1 plasma OPN has been found to be significantly elevated in a 
number of malignancies compared to healthy individuals or patients with benign 
disease. In several malignancies plasma OPN is suggested as a useful prognostic 
marker. Levels of OPN in plasma appear to correlate with pathological data such as 
stage or grade of tumor. In some malignancies OPN has a tendency to increase in 
plasma of patients with metastatic tumors. Moreover, in breast cancer plasma OPN is 
associated with the number of organ sites affected by metastases, reflecting the 
extension of the disease. All these findings suggest that plasma OPN is a promising 
diagnostic marker for primary tumor or metastases and, moreover, could be of 
prognostic value for cancer patients. Plasma OPN in PCa patients is mentioned only in 
two reports and, therefore, many aspects of the subject have not been extensively 
studied. In fact, important data concerning the behavior of plasma OPN in PCa patients 
with different clinico-pathological characteristics are still not available. In contrast, in 
patients with RCC plasma OPN has not been evaluated so far. This indicates that more 
extensive research on plasma OPN in PCa and RCC patients is needed to elucidate its 
full diagnostic and prognostic potential in these malignancies. 
 
1.4.2 Structure of osteopontin 
 
OPN is a negatively-charged acidic hydrophilic protein of approximately 300 
amino acid residues detectable in all body fluids [4]. Its molecular weight ranges from 44 
kDa to 75 kDa due to differences in post-translational modifications [72]. OPN is 
aspartic acid-rich and highly phosphorylated on serines and threonines, endowing the 
protein with a high acidic character [73]. Structurally, OPN contains several domains 
that suggest its various functions (Figure 5): 
 
 Figure 5. Structure of OPN. Reproduced with permission from 
D. T. Denhardt, ref. [43]. 
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1.4.2.1 Arginine-glycine-aspartic acid domain - a ligand for cell integrin receptors 
 
A central region of OPN contains a tri-peptide RGD sequence, which is 
responsible for adhesion to cell surface integrin receptors (Figure 5) [45]. Integrins 
comprise a large family of cell receptors composed of two subunits, α and β. To date, at 
least 15 α and 8 β integrin subunits have been identified and each combination 
mediates certain functions and elicits specific signaling pathways [74]. Integrin receptors 
are multifunctional molecules capable of transmitting biochemical signals from the ECM 
to the cells interior. In fact, the cytoplasmic tail of β subunit is connected to the specific 
components of the cytoskeleton such as talin and paxillin. Activated integrins and 
cytoskeletal proteins assemble into aggregates, which potentiate transmembrane 
signaling events. Integrins further activate protein tyrosine kinases, including focal 
adhesion kinase (FAK) and Src-family kinases. Such integrin-dependent interactions 
alter gene expression in cell and regulate cell motility, growth, and survival [75,76]. 
 
1.4.2.2 Thrombin cleavage site 
 
OPN can be cleaved by thrombin in close proximity to the RGD cell-binding 
region (Figure 5). Cleavage of OPN occurs under physiological conditions and could 
serve as an important mechanism to regulate the bioactivity of OPN. Thrombin cleavage 
allows greater accessibility of the RGD domain to cell surface receptors. In the study by 
Senger et al. [77] thrombin-cleaved OPN promoted markedly greater cell attachment 
and spreading than intact molecule. This fact of cleavage by thrombin restricts the 
quantification of OPN to plasma samples. Indeed, as a preliminary preparation to this 
study OPN was assayed with ELISA in matched serum and plasma samples of healthy 
individuals and RCC patients. OPN was only measurable in plasma whereas in serum 
OPN was not detectable apparently due to the susceptibility of OPN to thrombin 
(unpublished results). 
 
1.4.2.3 Serine-valine-valine-tyrosine-glycine-leucine-arginine sequence (SVVYGLR)  
 
As shown in Figure 5, SVVYGLR sequence consists of seven residues of amino 
acid and is located between the RGD domain and the thrombin cleavage site. Two 
integrin receptors, α9β1 and α4β1, are known to bind to SVVYGLR sequence. This 
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domain is also termed cryptic because it is functional only after cleavage by thrombin 
[78,79]. 
 
1.4.2.4 Other domains 
 
OPN contains two domains with heparin-binding properties that are likely to 
mediate its binding to ECM (Figure 5). Presence of putative Ca2+binding motifs probably 
explains the ability of OPN to bind large amounts of Ca2+ and interact with 
hydroxyapatite with high affinity [73]. OPN is also a ligand for several splice variants of 
CD44 cell receptor such as CD44v3-v6. The domains of OPN responsible for binding 
the CD44v3-v6 variants have not been established [73,80]. 
 
1.4.3 Biological functions of osteopontin 
 
OPN exists both as an immobilized ECM molecule in mineralised tissues and as 
a cytokine in body fluids [43]. Due to its multidomain structure OPN regulates various 




Figure 6. Biological functions of OPN. 
 
1.4.3.1 Bone resorption 
 
OPN is abundantly distributed in bone and is estimated to comprise 
approximately 2% of non-collagenous proteins in bone tissue [7,73]. OPN is involved in 
the regulation of bone turnover and secreted by both bone cells: osteoblasts and 
osteoclasts [5,73]. Osteoclasts are known to highly express αvβ3 integrin. [81]. Through 
the interaction with αvβ3 integrin OPN mediates migration and adhesion of osteoclasts 
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to bone matrix and, consequently, initiates a resorptive process [6,73]. In vitro and in 
vivo studies support the importance of the interaction between OPN and αvβ3 integrin 
of osteoclasts. Interference with the function of OPN or αvβ3 integrin using a variety of 
approaches leads to an inhibition of the adherence of osteoclasts and results in 
decreased bone resorption [82,83]. 
 
1.4.3.2 Mineralization and crystallization  
 
  OPN is assumed to play a role in regulating the deposition of mineral in bone and 
has been shown in vitro to inhibit hydroxyapatite crystal growth. The inhibitory activity of 
OPN is apparently due to both polyaspartic acid sequence and phosphate groups. In 
fact, interference with the phosphate groups or modification of carboxylate groups of 
aspartic acids reduced the inhibitory activity of OPN by a factor of 40 and 6, respectively 
[84]. 
OPN appears to be an important natural defense against renal crystallizations 
and nephrolithiasis. In vitro data indicate that urinary OPN may inhibit the formation of 
calcium oxalate crystals [85]. In a recent study with ethylene glycol-induced 
hyperoxaluria OPN knockout mice developed crystal formation and retention in kidney 
whereas wild types were completely unaffected [86]. Possibly due to its polyaspartic 
acid structure OPN also directs calcium oxalate (CaOx) crystallization to the CaOx 
dihydrate phase, which is markedly less adherent to renal tubular epithelial cells 
compared to the CaOx monohydrate [87,88]. OPN is present in human urine at levels 
that can efficiently inhibit CaOx crystallization [89]. Lower concentrations of OPN were 
found in the urine of patients with renal stone disease compared with normal individuals 
[90]. 
 
1.4.3.3 Inflammatory and immune response 
 
OPN plays an important role during acute inflammation where it may be 
synthesized by infiltrating macrophages. OPN is involved in the recruitment and 
retention of immune cells to inflamed sites [4]. Using a rat model, Giachelli et al. [91] 
demonstrated macrophage-rich infiltration and high OPN expression at sites of 
subcutaneous injection of bacterial chemotactic peptide, N-phormyl-methionyl-leucyl-
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phenylalanine and the inhibition of macrophage infiltration by application of OPN 
neutralizing antibodies. 
In addition to acute inflammation, OPN is also involved in chronic inflammation 
initiated by T cell-mediated immunity. O’Regan et al. [92] demonstrated an extensive 
OPN expression in T-cells in granulomatous disease such as sarcoidosis. In the same 
study OPN fragments generated by thrombin cleavage enhance markedly the adhesion 
and migration of T-cells and macrophages in comparison with the native OPN. A recent 
experiment with OPN-null mice showed that OPN-deficient mice had a defective 
immune response and were more sensitive to viral and bacterial infection. Moreover, 
macrophage synthesis of the two major regulators of cell-mediated immunity interleukin-
12 and interferon-γ was diminished in OPN-null mice compared to wild types. This 





Recently, there have been some reports indicating the importance of OPN in 
angiogenesis. Interaction between RGD region of OPN and αv integrin family of 
endothelial cells appears to play a crucial role in angiogenesis. Takagi et al. [93] 
showed a hypoxia-induced increase in expression of OPN as well as αvβ3 and αvβ5 
integrins in retina. This evidence suggests that co-upregulation of the αv integrin family 
and OPN may potentiate neovascularization in ischemic retina. A recent study has 
revealed another possible mechanism by which OPN regulates angiogenesis. 
According to that study OPN-derived synthetic peptide SVVYGLR not only promotes 
adhesion and migration of endothelial cells but also stimulates lumen formation in vitro 
as efficiently as vascular endothelial growth factor (VEGF) [94]. In addition, OPN 
delivers an antiapoptotic signal to the cell via the αvβ3 integrin and thus promotes the 
survival of endothelial cells [95]. 
 
1.4.3.5 Osteopontin in tumor progression and metastasis 
 
Metastasis is the process by which cancer cells detach from the primary tumor, 
travel to a distant site via the circulatory system and form a secondary tumor. Several 
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events are necessary for malignant cells to leave the primary tumor and proliferate at a 
distant site: cell proliferation, invasion (cell motility, ECM degradation), and 
angiogenesis [96]. OPN appears to be implicated in all these events and, therefore, is 
recognized as a key protein in tumor progression. In the following sections experimental 
evidence, which supports this view, will be reviewed. 
Proliferation. OPN contains an RGD sequence that binds to integrins and is 
capable of promoting the proliferation of tumor cells. In this regard, Thalmann et al. [97] 
clearly demonstrated the stimulatory effect of OPN on the growth of PCa cells, in which 
OPN antibody inhibits the growth stimulatory effect by endogenous OPN and addition of 
exogenous OPN returns growth to a normal rate. Obviously tumor cells support their 
growth by secreting OPN and, as a consequence, OPN expression in tissue directly 
correlates with tumor size and stage [47,98]. On the other hand, OPN serves as a 
survival factor for tumor cells due to its ability to inhibit the synthesis of nitric oxide (NO) 
by activated immune cells. Generation and release of NO is known to be lethal for both 
host cell and tumor cell due to inactivation of critical metabolic pathways. Therefore, 
tumor cells that produce OPN may protect themselves from oxidative damage [99,100]. 
Moreover, recent data also showed that OPN delivers antiapoptotic signal to the cell 
[95]. Since tumor growth, either primary or metastatic, is merely defined by the number 
of cells in proliferation and cells that undergo apoptosis, the mechanisms described 
above could explain the association between OPN and tumor growth. 
Invasion. Enhanced motility of tumor cells as well as the ability to intravasate into 
the vasculature are known to play a crucial role in tumor invasion and metastasis [101]. 
OPN was shown to induce cell migration in breast cancer cells [102] and facilitate 
intravasation of PCa cells [103]. Distinct increase in OPN expression found in metastatic 
lesions compared to that of primary tumor emphasizes the importance of OPN in the 
invasion and spreading of tumor cells [103]. On the other hand, degradation of ECM is 
also important for cellular migration and invasion. In this regard, ECM-degrading 
proteases such as urokinase type plasminogen activator (uPA) and MMPs appear to be 
of major importance [104,105]. Through its adhesive properties, OPN can induce 
changes in tumor cell gene expression including induction of proteolytic enzymes. In 
this respect, Tuck et al. [102] demonstrated that OPN induces uPA expression and 
cellular invasiveness of breast epithelial cells. In another study OPN and uPA 
expression was found to be higher in bone metastases and invasive carcinomas than in 
non-invasive or normal breast tissue [106]. In murine melanoma cells, OPN was also 
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shown to increase pro-MMP2 expression and activation, cell migration, and ECM 
invasion leading to enhanced tumorigenicity [107]. 
 Angiogenesis. OPN appears to play an important role in tumor growth through 
the enhancement of angiogenesis [108]. OPN promotes adhesion, migration, and 
proliferation of endothelial cells, and, moreover, enhances their survival [93-95]. 
Generation of new blood vessels is important for the growth of both primary and 
metastatic tumors since cell proliferation requires continuous supply of oxygen and 
nutrients. A high degree of tumor vascularization also increases the chance for tumor 
cells to enter the circulatory system and metastasize [109]. Moreover, increased tumor 
vascularity is known to be associated with tumor progression and poor survival of tumor 
patients [110,111]. 
Tumor cell αvβ3 integrin. Considerable evidence suggests the implication of the 
αvβ3 integrin in increased malignancy of tumor cells. Tumorigenic and highly metastatic 
breast epithelial cells migrate toward OPN in an αvβ3-dependent manner while non-
malignant and less malignant epithelial cells do not express αvβ3. Migration of the latter 
cells to OPN is mediated by αvβ5 and αvβ1 integrins [52,112]. Moreover, transfection of 
the less malignant cells lacking αvβ3 with β3 enhances cell adherence, migration and 
invasiveness in vitro and also results in increased tumorigenesis in vivo [52]. In other 
cell types such as PCa cells, the highly invasive tumor cells are shown to express αvβ3 
in contrast to non-invasive tumor cells [113]. Most interestingly, nearly all breast cancer 
and PCa cells that have metastasized to bone express αvβ3 integrin [114,115]. 
Collectively, these observations indicate that OPN and interaction particularly with αvβ3 
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1.5 Objectives of study 
As described earlier, OPN, a glycoprotein, with its multidomain structure participates 
in various physiological and pathological processes. In relation to tumor biology 
numerous experimental studies indicate the implication of OPN in tumor progression 
towards metastasis [3]. In brief, in vivo and in vitro data showed elevated expression of 
OPN in metastatic lesions [103] and in cancer cells with highly invasive properties [102]. 
OPN expression in tissue correlates with tumor stage [47] and survival of cancer 
patients [48]. In addition, OPN, a secreted protein, is present in all body fluids [4] and 
therefore is available for routine determinations in plasma. All this suggests that 
evaluation of OPN in plasma could be of diagnostic value in relation to metastasis and 
could provide prognostic information regarding cancer patients. As mentioned earlier, 
plasma OPN in RCC patients has not been evaluated so far, whereas in PCa patients it 
is only available in a limited number of reports. 
Therefore, the current study was undertaken to investigate the diagnostic and 
prognostic usefulness of plasma OPN in PCa and RCC patients in comparison with the 
established bone markers such as ICTP, PINP, and bALP. The following aspects were 
examined: 
 
1. Concentrations of plasma OPN and the bone markers in controls and different 
subgroups of PCa and RCC patients classified according to the TNM system. 
2. Behavior of plasma OPN in PCa and RCC patients with different tumor stages 
and grades. 
3. Correlation of plasma OPN with the bone markers. 
4. Diagnostic accuracy of plasma OPN in comparison with the bone markers in the 
detection of distant metastases, especially bone metastases, in PCa and RCC 
patients. 
5. Ability of plasma OPN in comparison with the bone markers to predict the 
probability of distant metastasis in PCa and RCC patients. 
6. Possibility to increase diagnostic accuracy by combination of biomarkers using 
logistic regression approach. 
7. Prognostic significance of plasma OPN in comparison with the bone markers to 
predict the survival outcome in PCa and RCC patients. 
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2 Materials and methods 
2.1 Study population 
2.1.1 Control groups 
 
The control group for PCa patients consisted of 29 men whereas that for RCC 
patients included 27 females and 25 males (Tables 2 and 3). Participants in both control 
groups received no medication known to interfere with bone metabolism and had no 
signs of infection; gastrointestinal, hepatic, cardiac, or renal disease, tumors, or 
immunologic disease. In addition, liver and kidney diseases were excluded since all 
subjects had values of alanine aminotransferase and creatinine within the reference 
intervals. 
2.1.2 Patients with benign prostatic hyperplasia 
 
Thirty-five men who were classified as benign prostatic hyperplasia (BPH) 
patients received no treatment for prostatic disease at the time of blood sampling. The 
clinical diagnosis of BPH was histologically confirmed by examining prostatic specimens 
obtained by ultrasound-guided biopsies or after transurethral resection (Table 2). 
 
2.1.3 Prostate cancer patients 
 
There were 90 patients (median age 65 years, range, 38-77) with PCa (Table 2). 
PCa was diagnosed histopathologically by microscopic examination of prostatic 
specimens after biopsy or additionally at radical prostatectomy. Cancer stage was 
assigned according to the TNM system and histological grade was classified as grade 
1, 2 or 3. Gleason score was not available in all PCa patients. Bone scintigraphy and, in 
special cases, X-ray, computerized tomography or magnetic resonance imaging were 
used to diagnose bone metastases. There were 28 patients with bone metastases 
(indicated as group M1). The 62 patients without distant metastases received surgical 
staging (pelvic lymphadenectomy) with histological examination and were therefore 
subdivided into groups without (pN0M0, n=32) and with (pN1M0, n=30) lymph node 
metastases. In the pN1M0 group, 19 patients were untreated and 11 received hormonal 
therapy (orchidectomy, luteinizing hormone-releasing analogs, and antiandrogens) 
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before sample collection (median 2.1 months, range 0.8-3.2). In the M1 group, 12 
patients were untreated and 16 received hormonal therapy or had this treatment after 
radical prostatectomy or radiotherapy before sample collection (median 18.4 months; 
range 6.3 to 56). 
 
Table 2. Characteristics of controls, BPH, and PCa groups 
 








29 35 32 30 28 
Age (years)1 50 (41, 51) 60 (68, 71) 64 (58, 69) 68 (63, 72) 65 (59, 69) 
Tumor stage      
T2   18 11 5 
T3   14 19 20 
T4   -- -- 3 
Tumor grade      
G1   2 1 -- 
G2   17 19 11 
G3   13 10 17 
1Values are medians, with lower and upper quartiles in parentheses. 
 
2.1.4 Renal cell carcinoma patients 
 
The RCC group included 80 patients (Table 3). Cancer stage and grade were 
assigned according to the TNM system. Data on histological types of RCC were 
available for 70 patients. According to the histological data, of those 70 patients 55 
(79%) had clear cell RCC, 8 (11%) and 2 (3%) patients presented with papillary and 
chromophobe types of RCC. Another 5 (7%) patients had unclassified histological types 
of RCC. Bone scintigraphy, X-ray, computerized tomography, magnetic resonance 
imaging, and ultrasound diagnostics were used to diagnose metastases. Regional 
lymph node dissections with histological examinations were performed in certain cases 
for staging purposes. RCC patients were therefore subdivided into three groups: those 
without metastases (N0, n=32), patients with lymph node metastases (N1, n=11), and 
37 patients with distant metastases (M1 group). The patients with distant metastases 
were in turn subdivided into groups with bone and without bone metastases. Table 3 
also outlines the number and character of additional distant metastases in M1 group. 
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Table 3. Characteristics of controls and RCC groups 
 












52 32 11 17 20 
Female 27 17 5 8 7
Male 25 15 6 9 13
Age (years) 1 52 (41, 60) 60 (58, 65) 62 (57, 67) 58 (57, 65) 62 (56, 68) 
Tumor stage      
T1  19 4 4 3 
T2  6 2 4 5 
T3  7 4 8 11 
T4  -- 1 1 1 
Tumor grade      
G1  2 1 -- -- 
G2  25 5 8 9 
G3  5 5 9 11 
Additional metastases in M1 group2
With bone metastases Without bone metastases 
bone (2) lung (7) 
bone + lung (7) liver (2) 
bone + liver (1) duodenum (1) 
bone + mediastinum (1) lung + liver (1) 
bone + lung + mediastinum (1) lung + CNS (1) 
bone + lung + CNS (2) thyroidal gland + mediastinum (1) 
bone + lung + mediastinum + CNS (2) lung + liver + pancreas (2) 
bone + lung + liver + pancreas + skin (1) lung + liver + duodenum (1) 
 lung + liver + CNS + vagina (1) 
1Values are medians, with lower and upper quartiles in parentheses. 
2Number of patients with respective metastases in parentheses. 
Abbreviation: CNS, central nerve system. 
2.2 Collection of blood samples 
 
 Controls and patients in this study were investigated at the Department of 
Urology, Charité University Hospital. Blood samples were collected in plastic tubes 
containing K-EDTA for OPN determination or kaolin-coated granulate for the 
quantification of other analytes (Monovette systems, Sarstedt, Nümbrecht, Germany) 
between 7:00 and 9:00 a.m. and centrifuged at 2,000g for 10 min at 4°C within 2 hours 
after venipuncture. Supernatants were stored at –80°C for further analysis. 
2.2.1 Prostate cancer 
 
In PCa patients blood samples were collected before any treatment except in the 
groups pN1M0 and M1 as mentioned in 2.1.3. In all other cases, blood samples were 
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taken before any diagnostic procedure, transurethral resection of the prostate, 
prostatectomy or 4 weeks after digital rectal examination, prostatic biopsy or transrectal 
ultrasound. 
 
2.2.2 Renal cell carcinoma 
 
In RCC patients blood samples were collected before any treatment except in the 
group of patients with distant metastases. In the group of 17 patients with bone 
metastases, blood was taken from 11 patients one day before radical nephrectomy and 
from 26 patients between 2 and 72 months after radical nephrectomy at a control 
examination at our institution. In the group of 20 patients without bone metastases, 
blood samples were collected from 13 patients one day before surgery, from 3 patients 
3-72 months after radical nephrectomy at a control examination, and from 4 patients at 
the time of the diagnosis of metastases.  
2.3 Quantification of osteopontin 
2.3.1 Sample preparation 
 
The ELISA technique was used to quantify OPN in K-EDTA plasma from PCa 
and RCC patients and in respective controls. Samples were brought to a room 
temperature and rested till completely thawed. After short vortex and visual check, 
samples were centrifuged at 5000g and 4°C. Assay buffer provided in ELISA kits was 
used to dilute plasma samples to a desired proportion. 
 
2.3.2 The ELISA procedure 
 
Figure 7 schematically illustrates ELISA procedure used for OPN quantification: 
(a) each well of ELISA plate was coated with a capture antibody to human OPN; (b) 
standards and samples were diluted with assay buffer and added to the wells; OPN, if 
any present, bound to the immobilized antibody building antigen-antibody complex; (c) 
the plate was incubated and washed so that excess OPN and unbound non-specific 
antigens were washed away whereas captured OPN remained in the wells for further 
quantification; (d) enzyme-linked antibody was added to the wells and coupled to the 
previously formed antigen-antibody complex; (e) the plate underwent incubation and 
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wash for a second time so that labelled molecules that did not bind could be removed; 
(f) a colorless substrate was applied to the wells; (g) the reaction between the enzyme 
and the substrate converts the latter to generate color; (h) adding stop solution 
terminated the enzymatic reaction and (i) the color signal was finally estimated by 
spectrophotometry; the color intensity in each well was directly proportional to the 












a) Antibody to OPN 
is attached on the 
well 
 b) OPN binds to 
antibody 
 c) OPN-antibody 
complex 












d) Labelled antibody 
is added 
 e) Labelled antibody 
binds to OPN-
antibody complex 
 f) Substrate is 
applied 










g) Substrate is 
generating color 
 h) Color development 
is stopped 
 i) Color intensity is 
proportional to OPN 
concentration 
 
Figure 7. The ELISA procedure for OPN quantification. 
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Plasma OPN from PCa patients was quantified with ELISA kits manufactured by 
Calbiochem® which were later not available for purchase. Further quantification of 
plasma OPN from RCC patients proceeded with ELISA kits produced by 
TiterZyme®EIA. Therefore, detailed information on each ELISA assay performed in 
plasma from PCa or RCC patients is outlined in Table 4. 
 
Table 4. ELISA assays used for OPN quantification in plasma of PCa and RCC patients 
 
 PCa RCC 
   
Manufacturer Calbiochem®. USA TiterZyme®EIA. USA 
   
Number of wells   
per plate 96 96 
   
Antibody detects whole OPN epitop of OPN1
   
Standards, µg/L 5, 10, 20, 40, 80, 160, 320 2, 4, 8, 16, 32 
   
Sample, dilution Plasma, 1:10 Plasma, 1:10 
   
Final standard or 
sample volume 
100 µL 100 µL 
   
Incubation I 1 hour, RT, on a shaker 1 hour, RT, on a shaker 
Wash I 7 x 400 µL 4 x 400 µL 
   
Antibody 100 µL 100 µL 
Enzyme label Horseradish peroxidase Alkaline phosphatase 
   
Incubation II 2 hours, RT, on a shaker 1 hour, RT, on a shaker 
Wash II 9 x 400 µL 4 x 400 µL 
   
Substrate Tetramethyl benzidine, 100 µL p-Nitrophenyl phosphate, 100 µL 
Incubation III 30 min, RT, on a shaker, dark 30 min, RT, on a shaker 
   
Stop solution Sulphuric acid, 100 µL, Trisodium phosphate, 25 µL 
1Epitope is located after thrombin cleavage site and includes SVVYGLRSKSK sequence. 
 
Note: Volume is given per well. Samples and standards were run in duplicate. 
TiterZyme®EIA kit required that two extra chemicals be added to the assay buffer in order 
to maintain OPN integrity in all samples and standards during the assay. Therefore 
Proteinase Inhibitor Cocktail (Sigma, St. Louis, MI; 0.5 µL/mL) and phenylmethylsulfonyl 
fluoride (1 mol/L) were added to the assay buffer. 
 
2.3.3 Calculation of osteopontin concentration 
 
The intensity of the color generated in the plate was measured optically with the 
spectrophotometer (Anthos HtII, Anthos Labtec Instruments, Salzburg, Austria) at 450 
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nm with the reference wavelength set at 620 nm. The spectrophotometer was interfaced 
to a personal computer to analyse data obtained with the software (MikroWin 3.0, 
Mikrotek Laborsysteme, Germany). Standard curves were constructed using 4-
parameter logistic curve fitting approach with known OPN concentrations of standards 





 Optical Density 
(mean) 
 

























Figure 8. Example of standard curve for OPN. 
 
Therefore, OPN concentrations of all samples within the plate could be determined 
with the standard curve. As shown in Figure 8 two samples of RCC patients with the 
coded numbers G362 and G890 had optical densities 0.096 and 0.223. Their 
concentrations calculated from the standard curve amounted to 1.70 and 6.15 µg/L. 
Taking into consideration that samples for the assay were diluted in proportion 1:10 
(Table 4) their actual OPN plasma level should be 17.0 and 61.5 µg/L. All 
measurements described above were performed by the author. 
 
2.4 Quantification of bone markers 
 
tALP was measured with standard enzyme assay on the Modular analyzer (Roche, 
Mannheim, Germany). PINP (Total PINP-Assay, Roche) was measured on the Elecsys 
2010 analyzer. The quantification of the above-mentioned markers was performed at 
the Institute of Laboratory Medicine and Pathobiochemistry at the Charité (Prof. Dr. E. 
Köttgen – at that time the director of the institute). bALP was determined by the 
Tandem-MP Ostase Immunoenzymetric Assay (Beckman Coulter, Fullerton, CA, USA), 
which specifically quantifies skeletal ALP with low immunoreactivity for liver/kidney 
isoforms. ICTP was quantified with ELISA (Orion Diagnostica, Espoo, Finland). These 
measurements were performed in the Research Laboratory of the Department of 
Urology, CCM with the kind assistance of Ms. Janet Reiche and Ms. Silke Klotzek to the 
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author of the dissertation. In RCC patients only ICTP and bALP were measured due to 
sample availability. 
2.5 Routine clinical chemistry determinations 
 
Alanine aminotransferase (ALAT) (upper reference limit 41 U/L), gamma-glutamyl 
transferase (GGT), C-reactive protein (5 mg/L), and creatinine (105 µmol/L) were 
measured by standard assays on the Modular analyser and were partly taken from the 
patient’s records. Total prostate specific antigen (PSA) was quantified with the Immulite 
PSA kit (Diagnostic Products, Los Angeles, CA, USA). 
 
2.6 Statistical analysis 
 
Statistical calculations were performed with SPSS 13.0 for Windows (SPSS, 
Munich, Germany) and GraphPad Prism 4.3 (GraphPad, San Diego, CA). The following 
tests were used: the non-parametric Kruskal-Wallis ANOVA with Dunn’s post-test, the 
Mann-Whitney U test, Spearman’s rank correlation coefficients (rs), and the distribution 
fitting procedure of Kolmogorov-Smirnov. Logistic regression approach was used to 
identify significant predictors of bone metastasis. The Kaplan-Meier product-limit 
method was used to determine survival probability for subgroups. Univariate and 
multivariate analyses of risk factors predicting PCa or RCC-specific death were 
performed using the Cox proportional hazards regression model. 1000 bootstrap re-
samples with the software R, version 2.3.1 (www.r-project.org) were partly used to 
estimate the parameters of the models and to prevent an overfitting bias. Bootstrap 
calculations were performed by Dr. Keller, Addstats, Leipzig. Diagnostic accuracy was 
evaluated by receiver operation characteristics (ROC) curve analysis using the software 
MedCalc 9.0.1.0 (MedCalc, Mariakerke, Belgium). Reference intervals were calculated 
according to the recommended procedure of the International Federation of Clinical 
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3 Results 
3.1 Prostate cancer 
3.1.1 Levels of osteopontin and bone markers 
 
Figure 9 shows the scatter plots and medians of OPN and bone markers in 
controls, BPH patients, and PCa patients subdivided into the groups N0M0, N1M0, and 
M1. Statistical assessment of the data can be summarized as follows: 
 
(i) Concentrations of all analytes did not differ among controls, BPH group, 
PCa with lymph node-negative and lymph node-positive groups except 
OPN where BPH patients showed a higher concentration than controls 
(P <0.01). 
(ii) OPN and all bone markers were significantly higher in patients with 
bone metastases compared to controls, BPH, and the N0M0 and N1M0 
groups (P <0.05 at least), showing their relationship with skeletal 
involvement. 
(iii) Significant differences were observed for OPN and all bone markers 
between PCa patients with and without bone metastases. 
 
Concentrations of OPN and bone markers in M1 group were evaluated in relation to the 
95 percentile cutoffs of the controls. In this regard 79% of the M1 patients had increased 
OPN values compared to 71%, 68%, and 63% of patients with increased values of 
ICTP, bALP, and PINP, respectively. 
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Figure 9. Scatter plots of OPN and bone markers in controls and patients with 
BPH or PCa. Median values of the groups are shown as horizontal lines with 
corresponding figures; dotted lines indicate the upper 95 percentiles of controls. 
Significant differences (Kruskal-Wallis non-parametric ANOVA with Dunn’s post-
test, P<0.05 at least) are shown by the following symbols; a, compared to 
controls; b, compared to BPH patients; c, compared to PCa patients without 
lymph node metastases (group pN0M0); d, compared to PCa patients with lymph 
node metastases (group pN1M0); e, compared to PCa patients with bone 
metastases (group M1). 
 
3.1.2 Correlation between osteopontin, bone markers, and clinico-pathological data 
 
Spearman’s rank correlation analyses were performed with all PCa patients as 
shown in Table 5. Significant correlations were observed between OPN and all bone 
markers (rs=0.43-0.79, all P <0.01). Moreover, OPN correlated with tumor grade 
whereas bALP correlated with tumor stage. Concentrations of OPN compared in 
different tumor grades of PCa patients ranged from 40 to 3388 µg/L with the median of 
3.9-
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838 µg/L in G1-2 tumors and from 412 to 8057 µg/L with the median of 994 µg/L in G3 
tumors (Mann-Whitney U test, P=0.044). Levels of bALP compared in different tumor 
stages of PCa patients ranged from 4.3 to 1006 ng/L with the median of 8.8 ng/L in 
stage II tumors and from 4.5 to 874 ng/L with the median of 10.9 ng/L in stage III+IV 
tumors (Mann-Whitney U test, P= 0.038). ICTP and PINP showed no association with 
tumor stage or grade. bALP correlated negatively with age. PSA significantly correlated 
with OPN and all bone markers (rs=0.30-0.37, all P <0.01). 
 
Table 5. Correlation between OPN, bone markers and clinico-pathological data 
 
 ICTP bALP PINP PSA Age T-Stage Grading 
OPN 0.54** 0.43** 0.49** 0.32** 0.17 0.21 0.23* 
ICTP 1.00 0.48** 0.61** 0.37** 0.05 0.08 0.17 
bALP  1.00 0.79** 0.37** -0.24* 0.24* 0.16 
PINP   1.00 0.30** -0.13 0.14 0.07 
PSA    1.00 -0.09 0.23* 0.29* 
Age     1.00 -0.04 0.08 
Significances: *, P <0.05; **, P <0.01. 
 
The effect of the hormonal therapy on OPN and on the other markers was 
subsequently evaluated. For this purpose their concentrations were compared in 
patients with and without treatment in the groups pN1M0 and M1, whereas the pN0M0 
group only included untreated patients. In the pN1M0 group, 19 patients were untreated 
and 11 had received hormonal therapy before sample collection (median 2.1 months, 
range 0.8 - 3.2) while 12 patients were untreated and 16 had received hormonal therapy 
in group M1 before sampling (median 18.4 months, range 6.3 – 56). In both groups, the 
concentrations of all markers did not differ between patients with and without hormonal 
treatment (Mann-Whitney U test; P values between 0.211 and 1.00). Consequently, all 
further calculations were performed with the data of all patients in the respective groups 
independently of the treatment. 
 
3.1.3 Osteopontin and bone markers as diagnostic indicators of metastases 
 
ROC analysis was used to assess the diagnostic usefulness of OPN and bone 
markers to differentiate PCa patients with and without bone metastases (Table 6). OPN 
and bone markers were effective for the detection of bone metastases with the largest 
area under the ROC curve (AUC) observed in ICTP, 0.88, followed by OPN, bALP, and 
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PINP, 0.85, 0.84, and 0.80 (all P <0.0001). There were no significant differences in AUC 
between the markers (P=0.164-0.937). However, at the cutoff level of 95% sensitivity, 
specificity of OPN outperformed that of bALP and PINP (P=0.0266 and 0.0009, 
McNemar test), but was less than that of ICTP (P=0.0002, McNemar test). At the same 
cutoff ICTP had the highest specificity. Similar to that, sensitivity of OPN and bone 
markers was examined at the cutoff level set at 95% specificity. However, at that point 
there were no differences in sensitivity of OPN and bone markers (P=0.30-1.0, 
McNemar test). 
 
Table 6. Diagnostic sensitivity, specificity and area under the curve (AUC) of 
OPN and bone markers to distinguish PCa patients with and without 
bone metastases 
 
Variable Sensitivity (%) Specificity (%) AUC 
    
OPN (µg/L)    
1192a 75 (55-89) 90 (80-96) 0.85 (0.76-0.91) 
1099b 75 (55-89) 86 (74-93)  
659c 95 (82-99) 31 (20-44)  
    
ICTP (µg/L)    
3.7a 82 (63-94) 81 (69-90) 0.87 (0.79-0.93) 
3.9b 71 (51-87) 82 (71-91)  
2.9c 95 (82-99) 63 (50-75)  
    
bALP (ng/L)    
15.2a 79 (59-92) 92 (82-97) 0.84 (0.75-0.91) 
20.5b 68 (48-84) 95 (87-99)  
5.8c 95 (82-99) 11 (5-22)  
    
PINP (µg/L)    
61.1a 70 (50-86) 94 (84-98) 0.80 (0.71-0.88) 
72.5b 63 (42-81) 95 (87-99)  
14.5c 95 (82-99) 3 (1-11)  
    
OPN+bALP    
0.2139a 89 (72-98) 87 (76-94) 0.93 (0.85-0.97) 
0.1024c 95 (82-99) 63 (50-75)  
 
Sensitivity, specificity, and area under the curves (AUC) with 95% confidence 
intervals in parentheses of the various markers were calculated using either 
athe cutoff level with the highest diagnostic accuracy obtained from ROC 
analysis performed with 62 patients without bone metastases and 28 patients 
with bone metastases or 
bthe cutoff level of 95 percentile of controls. 
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The possibility of increasing the diagnostic accuracy in the detection of bone 
metastases was examined by means of combination of markers. For this purpose the 
binary logistic regression approach was applied. To identify the significant predictors of 
bone metastasis in PCa patients, both univariate and multivariate logistic regression 
analyses were performed (Table 7). 
 
Table 7. Logistic regression analysis of OPN and bone markers in 
relation to bone metastasis in PCa1
 
I. Univariate analysis    
     
Variable RR (95% CI) P-value 
OPN 1.002 (1.001-1.003) <0.0001 
ICTP 1.325 (1.092-1.607) 0.004 
bALP 1.156 (1.075-1.243) <0.0001 
PINP 1.038 (1.019-1.057) <0.0001 
     
II. Multivariate analysis    
     
 Inclusion selection Stepwise selection 
Variable RR (95% CI) P-value RR (95% CI) P-value 
OPN 1.001 (1.00-1.003) 0.039 1.001 (1.00-1.003) 0.011 
ICTP 1.135 (0.92-1.393) 0.227 -- -- 
bALP 1.191 (1.03-1.378) 0.018 1.124 (1.05-1.207) 0.001 
PINP 0.979 (0.94-1.020) 0.315 -- -- 
 
1Calculated with PCa patients with bone (n=28) and without (n=62) bone 
metastases. 
 
Univariate regression model determined all four analytes OPN, bALP, PINP, and 
ICTP as significant factors. Significant variables were further analyzed in multivariate 
regression model to identify independent predictors of bone metastasis. OPN and bALP 
were the only independent predictors of bone metastasis in PCa patients. These results 
were also confirmed by multivariate analyses with stepwise selection where PINP and 
ICTP as insignificant variables were eliminated from the model while OPN and bALP 
remained in the model. The final regression equation was:  
logit(p)= -4.581+0.001*(OPN)+0.117*(bALP) where p was defined as the 
probability of the occurrence of metastasis. The Wald statistics showed values of 6.507 
and 10.653 for OPN and bALP, respectively, with corresponding significant P values of 
0.011 and 0.001. The overall model fit was characterized by the Nagelkerke value of R2 
= 0.621 demonstrating a good predictive efficacy. An overall correct classification of 
86% was obtained. The values obtained from the regression equation with these two 
analytes were used to construct a corresponding ROC curve. This two-marker 
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combination resulted in an increased AUC up to 0.93 compared to that of OPN (AUC, 
0.85; P=0.026) or bALP (AUC, 0.84; P=0.008) alone as shown in Figure 10. 
Overoptimism of the model referring to overfitting was estimated by a validation 
procedure using bootstrapping with 1000 cycles [117,118]. Overoptimism for AUC was 

















Figure 10. ROC curves for OPN, bALP and their 
combination to distinguish between PCa patients with 
and without bone metastases. AUC values ± standard 
errors were as follows: OPN, 0.85 ± 0.05; bALP, 0.84 ± 
0.05; combination of OPN and bALP, 0.93 ± 0.03. 
 
The AUCs of the OPN+bALP combination and ICTP were not significantly 
different (P=0.235). At the cutoff level of 95% sensitivity, the specificity of OPN and 
bALP as marker combination amounted to 63%, which was higher than that for OPN 
(31%) or for bALP (11%) alone, and achieved equal specificity as ICTP (Table 6). 
3.1.4 Osteopontin and bone markers as predictors of survival outcome 
 
Complete follow-up data were obtained in all 90 PCa patients, making each case 
eligible for survival analysis. Mean follow-up time was 39.2±18.2 months (range 2.7-
88.4). The primary end point of this analysis was cancer-related survival, as measured 
from the date of surgery or visit to the last follow-up or cancer-related death. According 
to the death certificates and the information of general practitioners, 13 patients died 
from PCa. To determine whether the concentrations of OPN and markers correlated 
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with disease outcome, patients were stratified into 2 groups using the cutoff points of 95 
percentiles of controls. To identify the significant prognostic factors associated with 
PCa-specific death, univariate and multivariate risk factor analyses were performed 
using the Cox proportional hazards regression model (Table 8). 
 
Table 8. Univariate and multivariate Cox regression analyses of OPN, bone markers, and 
clinico-pathological factors in relation to PCa survival1
 
I. Univariate analysis  
   
Variable Dichotomous criteria2 RR (95% CI) P-value 
OPN 1099 µg/L 13.8 (3.04-62.9) 0.001 
ICTP 3.9 µg/L 7.48 (2.06-27.2) 0.002 
PINP 72.5 µg/L 11.9 (3.62-39.2) <0.0001 
bALP 20.5 ng/L 9.26 (2.83-30.3) <0.0001 
PSA 10 ng/mL 3.37 (0.74-15.4) 0.117 
    
Age 60 years 1.36 (0.37-4.95) 0.639 
Tumor stage T1-2/T3-4 2.07 (0.55-7.82) 0.285 
Tumor grade G1-2/G3 2.39 (0.70-8.21) 0.167 
Bone metastases absence/presence 11.3 (3.03-42.3) <0.0001 
   
II. Multivariate analysis  
     
 Inclusion selection Stepwise selection 
Variable Dichotomous criteria2 RR (95% CI) P-value RR (95% CI) P-value
OPN 1099 µg/L 5.02 (0.76-33.4) 0.095 6.50 (1.17-36.2) 0.033 
ICTP 3.9 µg/L 1.84 (0.44-7.79) 0.406 -- -- 
PINP 72.5 µg/L 1.82 (0.35-9.45) 0.477 4.48 (1.17-17.2) 0.029 
bALP 20.5 ng/L 2.54 (0.42-15.3) 0.311 -- -- 
PSA 10 ng/mL -- --   
      
Age 60 years -- --   
Tumor stage T1-2/T3-4 -- --   
Tumor grade G1-2/G3 -- --   
Bone metastases absence/presence 1.24 (0.18-8, 8) 0.878 -- -- 
 
1All 90 PCa patients were available for analysis of independent prognostic significance. 
2Dichotomous criteria for each marker represents 95 percentile of the corresponding control 
group as also shown in Figure 9. 
 
Univariate Cox regression analysis revealed that the markers OPN, ICTP, PINP, 
and bALP as well as the presence of metastases were potential prognostic factors for 
survival in PCa patients with P <0.05 (Table 8). In Kaplan-Meier analysis, patients with 
concentrations of the above-mentioned 4 markers higher than the cutoffs had 
significantly shorter overall survival time than patients with low concentrations (Figure 
11). These significant variables were further evaluated in multivariate analysis with both 
inclusion and stepwise selection procedures. OPN and PINP were the only independent 
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negative predictors of survival in PCa after adjusting for the other factors significant in 
univariate analysis. In the stepwise elimination procedure (backward and forward), both 
OPN and PINP remained as significant prognostic factors in the model while other 
variables with less impact on survival were eliminated from the model (Table 8) 
 












































Figure 11. Cumulative cancer-related survival in PCa patients with OPN and 
bone marker concentrations below and above the cutoff points of 95 percentiles 
of controls. Cutoff points were taken from the data in Figure 9. Survival 
distributions were calculated using the Kaplan-Meier method and compared by 
the log rank test. All 90 PCa patients were included for survival analysis. 
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3.2 Renal cell carcinoma 
3.2.1 Levels of osteopontin, bone markers, and enzymes 
 
Levels of OPN, bone markers, and enzymes were compared in controls between 
groups with healthy men and women. Calculations showed that there were no 
differences in concentrations of biochemical markers between those two groups (P = 
0.2255 - 0.8683, Mann-Whitney U test) and, therefore, the gender-dependent variation 
of the markers in this study is most probably excluded. Based on these results, further 
evaluations of biochemical markers were performed with the cutoff points set at 90 
percentile of the control groups. Figure 12 shows the scatter plots and medians of OPN, 
bone markers, and enzymes in controls and RCC patients subdivided into the groups 
N0M0, N1M0, M1b and M1nb. Statistical assessment of the data can be summarized as 
follows: 
 
(i) OPN and ICTP levels had no significant differences between controls 
and the N0 group. 
(ii) Concentrations of OPN and ICTP in RCC groups with regional lymph 
node (N1M0) and distant bone and non-bone metastases (M1b, M1nb) 
were significantly higher than those in controls. 
(iii) Compared to the RCC group without metastases (N0), OPN values 
were significantly elevated in both M1b and M1nb groups, whereas 
ICTP values were elevated only in M1nb. 
(iv) Levels of the markers were not different between groups with distant 
bone (M1b) and non-bone (M1nb) metastases (P = 0.1384 - 0.9151, 
Mann-Whitney U test). 
(v) bALP and ALAT did not vary among controls and all RCC groups. 
(vi) GGT was elevated in the M1nb group in comparison to controls. 
 
In relation to the 90 percentile cutoffs 73% of patients in the groups with distant 
metastases (M1nb and M1b) had increased OPN concentrations compared to 69%, 
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Figure 12. Scatter plots of OPN (A), bone markers (B-C) and enzymes (D-E) in controls and RCC 
patients: without metastases (N0), with regional lymph node metastases (N1), and with distant bone 
(M1b) and non-bone (M1nb) metastases. Median values of the groups are shown as horizontal 
lines with corresponding figures. The dotted line on each graph represents the 90 percentile of 
controls. Significant differences (P<0.05 at least) are shown by the following symbols; a, compared 
to controls; b, compared to N0 group; c, compared to N1 group; d, compared to M1b group; e, 
compared to M1nb group. Levels of the markers between RCC groups with bone (M1b) and non-
bone (M1nb) metastases were compared by Mann-Whitney U test. 
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3.2.2 Correlation between osteopontin, bone markers, enzymes, and clinico-
pathological data 
 
Spearman’s rank correlation analyses were performed with all RCC patients. As 
shown in Table 9, a significant correlation was observed between OPN and each bone 
marker. As for enzymes, GGT correlated strongly with OPN, whereas ALAT showed no 
association with OPN. In relation to tumor stage or grade of RCC patients, levels of 
OPN associated more strongly with tumor stage than with tumor grade. Concentrations 
of ICTP correlated with both stage and grade more closely than concentrations of bALP. 
Association with stage was also observed in levels of GGT. 
Table 9. Correlation between biochemical markers and clinico-pathological data 
 ICTP bALP ALAT GGT T-Stage Grading 
OPN 0.50** 0.37** 0.02 0.43** 0.50** 0.33* 
ICTP 1.00 0.09 -0.28* 0.01 0.38** 0.37** 
bALP  1.00 0.29* 0.48** 0.26* 0.30* 
ALAT   1.00 0.45** 0.07 -0.08 
GGT    1.00 0.29* 0.18 
Significances: *, P <0.05; **, P <0.01. 
 
Biochemical markers that showed correlation with tumor stage or grade were 
subsequently analyzed with regard to their concentration range and median in different 
tumor stages and grades (Table 10). 
Table 10. Concentrations of OPN, bone markers, and GGT in different tumor stages 
and grades of RCC patients 
 
 OPN ICTP bALP GGT 
I. Stage of RCC     
 I 31 (14-557)bc 2.2 (1.2-86.8)c 8.8 (1.9-40.5) 13 (6-112) 
 II 82 (23-473)a 4.3 (1.8-16.6) 12.5 (5.3-31.7) 17 (6-48) 
 III+IV 116 (20-1778)a 5.1 (1.4-29.6)a 11.0 (2.8-55.7) 25 (7-254) 
     
P value1 0.0002 0.003 0.0501 0.065 
     
II. Grade of RCC     
 G1-2 46 (14-473) 3.3 (1.2-29.6) 9.0 (2.0-27.1)  
 G3 116 (32-1778) 5.8 (1.8-86.8) 15.4 (4.7-55.7)  
     
P value2 0.0377 0.0089 0.0010  
 
1Calculated with the Kruskal-Wallis overall test. Concentrations in different tumor 
stages were compared in pairs and significant difference (P<0.05 at least) shown as: 
a, compared to Stage I; b, compared to Stage II; or c, compared to Stages III+IV 
(Kruskal-Wallis with Dunn’s post test). 
2Calculated with the Mann-Whitney U test. 
 Note: values are medians with ranges in parentheses. 
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Plasma concentrations of OPN increased with progression of the malignancy. As 
shown in Table 10, OPN levels were significantly lower in RCC patients with stage I 
than in RCC patients with stage II or stages III+IV. Compared to OPN, a less significant 
difference was observed in ICTP levels in various tumor stages whereas concentrations 
of bALP and GGT did not differ in that manner. In addition, levels of OPN were higher in 
RCC patients with Grade 3 than in those with Grade 1 or 2. Compared to OPN, 
concentrations of ICTP and bALP differ more significantly in those two tumor grade 
groups. 
OPN concentrations were examined with regard to the number of organ sites 
affected by metastases. The difference in median levels of plasma OPN in RCC 
patients with metastatic lesions in one, two, and three or more organs were not 
statistically significant (Table 11). 
 
Plasma OPN and number of organs affected by  Table 11. 
metastases in RCC patients 
 




Median with range 
(µg/L) 
   
one 12 116 (41.8-301) 
two 13 152 (28.9-1778) 
three and more 12 101 (31.5-473) 
P=0.250 (Kruskal-Wallis overall test). 
 
In addition, plasma OPN levels were evaluated in relation to the histological types 
of RCC. Histological data were available in 70 cases. Plasma OPN compared in 
different histological types of RCC were not significantly different as shown in Table 12. 
 
Table 12. Plasma OPN and histological types of RCC patients 
 
Histological types Number of 
cases 
Median with range 
(µg/L) 
   
Clear cell 55  61 (6.3-1778) 
Papillary 8  51 (21.2-1019) 
Chromophobe 2  35 (31.6-37.5) 
Unclassified 5  69 (26.3-595.7) 
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3.2.3 Osteopontin and bone markers as diagnostic indicators of metastases 
 
Since only OPN and ICTP levels showed statistically significant differences 
among RCC groups (Figure 12), their diagnostic accuracies to differentiate RCC 
patients without metastases from those with distant bone and non-bone metastases 
were evaluated subsequently. The area under the OPN curve was significantly larger by 
0.181 in comparison with that of ICTP (Figure 13; P=0.018) and proved the superior 
diagnostic accuracy of OPN for the detection of distant metastases. At the cutoff for 
95% sensitivity (Figure 13), the specificity of OPN amounted to 57.1% (95% CI, 37.2-
75.5) and significantly outperformed (McNemar test, P=0.0309) that of ICTP with 25% 
(95% CI, 10.7-44.9). The points with the highest diagnostic accuracy were at the OPN 


















Figure 13. ROC curve to distinguish between 
RCC groups without metastases (N0) and with 
distant metastases (M1nb and M1b), 28 and 32 
patients in each group, respectively. AUC with 
95% CI in parentheses are shown in the lower 
right corner. 
 
Further ROC analysis was performed in the same fashion as described above 
with the exception that each group with distant bone (M1b) or non-bone (M1nb) 
metastases was analyzed separately. This was aimed at evaluating whether OPN had 
different diagnostic performance in distinguishing RCC patients with distant bone (M1b) 
or non-bone (M1nb) metastases from those with organ-confined disease (N0). However, 
ROC analysis showed that AUCs of OPN in relation to distant bone or non-bone 
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 ICTP  0.71 (0.56-0.82)  
 38
Chapter 3  Results 
metastases were almost equal and amounted to 0.86 (0.73-0.94) and 0.87 (0.75-0.95), 
respectively. ICTP was also evaluated using the same approach. In this respect, AUCs 
of ICTP in the detection of distant bone or non-bone metastases amounted to 0.69 
(0.52-0.82) and 0.75 (0.61-0.86) and there was no difference between ROC curves 
(P=0.112). 
OPN, bone markers, and enzymes were analyzed using univariate and 
multivariate logistic regression models in order to assess their ability to predict distant 
metastasis in RCC patients (Table 13). The univariate regression model determined 
OPN and bALP as significant factors related to the risk of distant metastasis whereas 
the other variables were less significant. All variables were further included in 
multivariate analyses with inclusion and stepwise selections in order to determine 
independent predictors of distant metastasis. OPN was proven in the multivariate model 
by both selections to be the only independent variable related to the risk of distant 
metastasis. 
Logistic regression analysis of OPN, bone markers, and Table 13. 
enzymes in relation to distant metastasis in RCC1
 
I. Univariate analysis    
     
Variable RR (95% CI) P-value 
OPN 1.02 (1.01-1.04) 0.004 
ICTP 1.12 (0.99-1.28) 0.098 
bALP 1.09 (1.00-1.18) 0.047 
ALAT 1.02 (0.94-1.12) 0.606 
GGT 1.02 (1.00-1.04) 0.091 
     
II. Multivariate analysis    
 Inclusion selection  Stepwise selection  
Variable RR (95% CI) P-value RR (95% CI) P-value 
OPN 1.03 (1.00-1.05) 0.019 1.02 (1.01-1.04) 0.004 
ICTP 0.92 (0.79-1.09) 0.346 -- -- 
bALP 1.01 (0.90-1.15) 0.820 -- -- 
ALAT 1.05 (0.91-1.21) 0.524 -- -- 
GGT 1.01 (0.98-1.04) 0.588 -- -- 
 
1Calculated for RCC patients with distant metastases  
 (M1b and M1nb groups) and without metastases (N0 group). 
 
As described earlier in Chapter 3.1.3, in PCa patients, using the logistic 
regression approach, the combination of two significant variables was considered in 
order to increase diagnostic accuracy in the detection of distant metastases. In RCC 
patients all other variables except OPN were insignificant in the multivariate logistic 
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regression model (Table 13), therefore, the possibility of increasing diagnostic accuracy 
using the same approach was not feasible. 
In order to investigate the diagnostic ability of OPN and the bone markers to 
group RCC patients according to different tumor stages and grades, biochemical 
markers were further examined with the ROC analysis. Based on the results from Table 
10 the diagnostic accuracy of OPN, ICTP, and bALP to differentiate between tumor 
stages I and II-IV or between tumor grades G1-2 and G3 was further evaluated as 










Figure 14 ROC curves of OPN, ICTP, and bALP to differentiate     
RCC patients with different tumor stages and grades. 
A.  Tumor stages: I versus II-IV. 
B. Tumor grades: G1-2 versus G3. 
 
In distinguishing RCC patients with tumor stage I from those with tumor stages II-
IV, OPN with AUC of 0.84 was more accurate than ICTP with that of 0.75 (Figure 14 A, 
Table 14 A). Difference between AUCs of both markers was not significant (P=0.189). 
However, when both markers were compared at the 80% specificity, the sensitivity of 
OPN amounted to 82 % (67-92) and was 40% higher than that of ICTP (P=0.0044, 
McNemar test). However, above the sensitivity of 80% there was no difference in 
diagnostic specificity between OPN and ICTP (Figure 14 A). The diagnostic 
performance of biochemical markers in differentiating RCC patients with tumor grades 
G1-2 and G3 was less effective (Figure 14 B, Table 14 B). The AUCs of OPN, ICTP, 
and bALP ranged from 0.67 to 0.76 and there was no difference between the AUCs of 
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Table 14. Diagnostic sensitivity, specificity and AUC of OPN and bone markers 
to distinguish different tumor stages and grades in RCC patients 
 
A. Tumor stages: I versus II-IV
    
Variable Sensitivity (%) Specificity (%) AUC 
OPN    
 46.5 µg/L 82 (67-92) 83 (57-96) 0.84 (0.78-0.92) 
    
ICTP    
 2.5 µg/L 86 (74-94.3) 67 (43-85) 0.75 (0.62-0.86) 
    
B. Tumor grades: G1-2 versus G3
    
Variable Sensitivity (%) Specificity (%) AUC 
OPN     
 46.5 µg/L 84 (60-96) 55 (36-73) 0.68 (0.53-0.80) 
    
ICTP     
 2.5 µg/L 95 (76-99) 44 (29-60) 0.67 (0.52-0.79) 
    
bALP     
 10.0 ng/L 81 (58-94) 63 (47-77) 0.76 (0.62-0.87) 
 
Sensitivity, specificity, and AUC with 95% confidence intervals in parentheses of 
the various markers were obtained from ROC analysis. Concentration of each 
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3.2.4 Osteopontin and bone markers as predictors of survival outcome 
 
The mean and median follow-up time was 47.9 ± 28.9 months and 47.9 months, 
respectively (range = 1.0 – 91.3 months). The primary end point of the analyses was 
cancer-related survival as measured from the date of surgery or presentation in our 
institution to the time of the last follow-up or cancer-related death. According to the 
death certificates and to information provided by the general practitioners, 20 patients 
died from RCC. To determine whether variables correlated to the disease outcome, 
patients were stratified into two groups by means of the cutoff points using the 90 
percentiles of the controls. To identify the significant prognostic factors associated with 
RCC-specific death, univariate and multivariate risk factor analyses were performed 
using the Cox regression model with the stratified groups (Table 15). 
 
Table 15. Univariate and multivariate Cox regression analyses of biochemical markers and 
clinico-pathological factors in relation to RCC survival1
 
I. Univariate analysis  
   
Variable Dichotomous criteria2 RR (95% CI) P value 
Age 60 years 0.80 (0.39-1.67) 0.568 
OPN 71.1 µg/L 3.55 (1.51-8.35) 0.004 
ICTP 3.8 µg/L 2.74 (1.26-5.96) 0.011 
bALP 17.6 ng/L 1.58 (0.71-3.54) 0.266 
ALAT 18.2 U/L 0.04 (0.00-15.0) 0.293 
GGT 40.6 U/L 1.61 (0.76-3.42) 0.217 
Tumor stage T1-2/T3-4 2.59 (1.19-5.64) 0.016 
Tumor grade G1-2/G3 2.34 (1.08-5.06) 0.031 
Metastases3 absence /presence 5.77 (2.47-13.5) 0.0001 
    
II. Multivariate analysis  
  Inclusion selection  Stepwise selection  
Variable Dichotomous criteria2 RR (95% CI) P value RR (95% CI) P value
Age 60 years - -   
OPN 71.1 µg/L 2.08 (0.67-6.45) 0.206 2.92 (1.04-8.16) 0.041 
ICTP 3.8 µg/L 1.90 (0.61-5.97) 0.271 - - 
bALP 17.6 ng/L - -   
ALAT 18.2 U/L - -   
GGT 40.6 U/L - -   
Tumor stage T1-2/T3-4 1.64 (0.52-5.21) 0.401 - - 
Tumor grade G1-2/G3 0.78 (0.29-2.13) 0.631 - - 
Metastases3 absence /presence 2.83 (0.92-8.71) 0.071 3.18 (1.13-8.93) 0.028 
 
1The Cox proportional hazards regression model was calculated with all 80 RCC patients. 
2Dichotomous criteria for each biochemical marker represents 90 percentile of the 
corresponding control group as also shown in Figure 12. 
3Included all metastatic patients: with the regional (n=11) and distant cases (n=37). 
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The levels of OPN and ICTP, as well as the tumor stage, grade, and the presence of 
distant metastases were found to be significant univariate prognostic factors of death 
from RCC. Patients with levels of OPN and ICTP above the cutoff point had significantly 
shorter survival time than patients with the levels of those markers under the cutoff 
points (Figure 15). The multivariate Cox regression analysis of these univariate 
significant predictors showed that none of them was an independent predictor of 
cancer-related death in that model (Table 15). However, the result of the forward or 
backward stepwise calculation to set up a reduced model was that only OPN and the 
presence of distant metastases retained statistical significance in the model. Thus, OPN 


















Figure 15. Cumulative cancer-related survival in RCC patients 
calculated with the Kaplan-Meier method and compared by 
the log rank test. 
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4 Discussion 
 
This chapter discusses the diagnostic and prognostic significance of OPN and the 
bone markers for PCa patients followed by that for RCC patients. A brief conclusion on 
the clinical usefulness of OPN in both tumor entities will close the chapter. 
 
4.1 Prostate cancer 
 
PCa has a distinct predilection to metastasize to bone. The mechanisms 
underlying the preferential homing to the bone are unclear. Several factors have been 
proposed to determine the mechanisms responsible for the involvement of bone in 
metastatic PCa. For example, experimental data suggest that osteoblast-derived growth 
factors appear to stimulate the proliferation of PCa cells [119]. Thus, bone provides a 
favorable environment for the potential growth of PCa cells. Another study emphasizes 
the importance of bone marrow endothelium to which PCa cells preferentially adhere 
[120]. Additional data suggest that PCa cells acquire osteomimetic properties and 
behavior becoming more osteoblast-like in order to metastasize, survive, and thrive in 
the bone environment. Indeed, PCa cells were shown to synthesize and secrete bone-
related proteins [121]. On the other hand, specific cell adhesion molecules such as OPN 
are also implicated in this multi-factorial process of preferential metastasis of PCa to 
bone. In fact, involvement of OPN in bone metastasis was demonstrated in vivo, where 
a 50% decrease in bone metastasis was observed in OPN-deficient mice compared to 
wild types [51]. Interaction of αvβ3 integrin and RGD-binding sequence of OPN appears 
to play a crucial role in PCa metastasis to bone sites [122]. In vivo and in vitro OPN was 
demonstrated to stimulate the proliferation and induce the invasive ability of PCa cells 
possibly by interaction with αvβ3 [97,103]. Most interestingly, PCa cells obtained from 
bone metastatic lesions were shown to express αv and β3 integrin subunits [114]. 
Based on these observations it may be concluded that OPN, first, as the most abundant 
non-collagenous protein in bone and, second, as a ligand for αvβ3 integrin, may 
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4.1.1 Levels of osteopontin and bone markers 
 
Significant elevation of OPN levels was found in PCa patients with bone 
metastases while OPN concentrations in patients without metastases were not different 
from controls (Figure 9). This distinct increase of plasma OPN in PCa patients with bone 
metastases clearly indicates its association with metastatic spread to bone. Moreover, 
compared to the bone markers OPN levels in patients with BPH were higher than in 
controls (Figure 9). In fact, BPH tissue specimens were also found to be positive for 
OPN [123]. These findings could be explained by the fact that BPH often has an 
inflammatory component, which is accompanied by additional OPN synthesis in immune 
cells [4,97]. 
The findings of unchanged OPN values in patients with localized cancer restrict 
the diagnostic capability of OPN to its application as a metastatic marker in PCa 
patients and classify OPN as an unsuitable marker for the early detection of PCa. That 
conclusion is in certain contrast to the suggestion of Fedarko et al. [53] who described 
OPN as a highly sensitive and specific marker with an AUC of 0.91 in discriminating 
PCa patients from controls. These authors determined total OPN using a protocol by 
which the complex of complement factor H and OPN was disrupted before OPN was 
measured. However, in that study the PCa patients were not characterized with regard 
to tumor stage and grade while most of the patients obviously had PSA >20 ng/ml. 
Moreover, these PSA concentrations are not typical for organ-confined PCa. Therefore 
the study population of Fedarko et al. [53] was presumably inappropriate to answer the 
question whether the assay of OPN, despite the use of the other method, is informative 
in the gray zone of PSA with concentrations between 2 und 10 ng/ml. In addition, the 
current data correspond to results of Hotte et al. [54] who showed OPN levels in 
hormone-refractory PCa patients with metastases. Since these authors did not present 
detailed data of patients with localized PCa, BPH, and healthy controls, the present data 
are the first results to allow a clear conclusion concerning the application of OPN as 
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4.1.2 Correlation between osteopontin, bone markers, and clinico-pathological data 
 
Plasma OPN in PCa patients correlated with tumor grade (Table 5). PCa patients 
with G3 tumor grade tended to have higher concentrations of OPN in plasma compared 
to their counterparts with G1-2 tumor grades. Median concentrations in those two 
groups were 994 and 838 µg/L, respectively. Although the difference between these two 
tumor grade groups was marginal with P value of 0.044 these results suggest that 
plasma OPN may reflect tumor progression. Elevation of OPN levels in higher tumor 
grades was also reported in patients with hepatic malignancy [60]. Plasma OPN 
strongly correlates with bone markers such as PINP, bALP, and ICTP (Table 5). In 
several studies bone markers are reported as indicators of tumor extension. In fact, 
PINP, bALP, and ICTP correlate with the number of metastatic lesions on bone scans 
known as Soloway grades [37-39]. This fact suggests that plasma OPN is associated 
with skeletal extension of metastatic PCa. 
 
4.1.3 Diagnostic performance of osteopontin and bone markers 
 
The diagnostic accuracy of OPN in the detection of bone metastases was 
comparable with that of the bone markers (Table 6). AUC value of OPN was higher than 
that of PINP and bALP. OPN had the highest percentage of values (79%) above its 
cutoff level in the group with bone metastases compared to that of ICTP, PINP, and 
bALP. In other malignancies such as metastatic breast cancer, this figure is 69% [56]. 
As bone metastases of prostate cancer are predominantly osteoblastic [8], a bone 
formation marker is supposed to be a good indicator of bone involvement. However, in 
this study ICTP, a bone resorption marker, had the largest AUC value and highest 
specificity at 95% sensitivity compared to the typical bone formation markers PINP and 
bALP (Table 6). This might be explained by the fact that bone lesions in PCa are not 
purely osteoblastic. Biochemical [124] and histological [125] evidence suggests that 
despite the osteoblastic nature of most PCa bone metastases, increased bone 
resorption occurs as well. Since in logistic regression analyses OPN and bALP were the 
only significant independent markers in relation to bone metastasis (Table 7), a 
combination of these two analytes was examined to enhance diagnostic accuracy in 
detection of bone metastases. OPN and bALP, in combination, increased AUC value up 
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to 0.93 compared with OPN (AUC, 0.85) and bALP (AUC, 0.84) curves (Table 6, Figure 
10). Therefore, combined measurement of OPN and bALP could provide a better 
diagnosis for bone metastases. Other authors have also considered the possibility of 
increasing the diagnostic accuracy via a combination of markers. For example, Withold 
et al. [126] obtained AUC of 0.84 for bALP and 0.76 for pyridinium cross-links (PYR) 
with respect to the detection of bone metastases. When these both markers were 
evaluated as a combination it resulted in an increase of AUC up to 0.89. 
 
4.1.4 Prognostic significance of osteopontin and bone markers 
 
Prognostic significance of OPN was evaluated in comparison to the bone 
markers. The association of survival was demonstrated in PCa patients with ALP, PINP, 
or ICTP corresponding to the extent of bone metastasis monitored by bone scans 
[12,124,127-129]. PSA was shown not to be directly associated with bone progression 
in several studies [127,129] and also in the current work (Table 8). In the present study, 
OPN and all bone markers were confirmed as significant predictors of death from PCa 
verified by the univariate Cox regression calculation (Table 8) and demonstrated by the 
survival curves of Kaplan-Meier analysis (Figure 11). Patients with marker levels below 
the cutoff of 95 percentile of the control group tended to have longer survival times 
compared to those with higher values of these markers. In the multivariate Cox 
regression analyses, OPN remained a significant independent prognostic factor of 
survival probability in PCa (Table 8). These data are in agreement with the findings 
obtained by Hotte et al. [54] that increased plasma OPN levels were associated with 
bone metastases and decreased survival in patients with PCa. Correlation of plasma 
OPN with decreased survival was also observed in malignancies including breast, 
esophagus, head, and neck cancers [56,69,70]. In addition, a recent study on OPN 
protein expression in PCa tissue showed that an increased level of OPN expression 
was significantly associated with reduced survival time of the patients [48]. These data, 
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4.1.5 Limitations of the study 
 
Some limitations of this study should be recognized. First, the limited number of 
patients could be seen as the main limitation of the present study. In contrast to this 
limitation, it is remarkable that even with the low statistical power due to the sample 
size, significant results of OPN were obtained. Thus, the risk of type II error, a problem 
associated with small studies, does not exist in the current study. In addition, the 
possibility of an overfitting bias for the calculated models due to the small sample size 
could be excluded as far as possible by additional bootstrapping calculations as shown 
in the results [117,118]. There was only a low proportion of overoptimism for the AUC 
calculated with the final model. Second, the present study is limited by its retrospective 
nature with blood sampling at different times. However, all measurements were 
performed in a blinded manner. Third, the groups with positive lymph nodes and distant 
metastases included patients with and without hormonal treatment. It was shown that 
hormonal therapy influences bone turnover although the study data based on different 
treatment regimes and duration of treatments are not at all consistent concerning the 
various bone markers [37,39,130-133]. In the present study, the concentrations of OPN 
and bone markers did not significantly depend on the hormonal treatment status 
showing P values >0.2 so that an interfering effect of the hormonal treatment on the 
diagnostic and prognostic capability is most probably excluded. The duration of 
treatment, in addition to the limited number of patients, could be one reason that 
explains the finding of no differences between treated and untreated patients. The 
median treatment period of 2.1 months in the pN1M0 group before sample collection 
was probably too short to have any effect upon the bone marker concentrations. For 
example, changed concentrations of ICTP were only observed after an antiandrogen 
therapy of 12 weeks, while PINP did not change during such treatment [37,39]. The 
missing marker differences between the group of pN0M0 that consisted only of 
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4.2 Renal cell carcinoma 
 
As described earlier in the Introduction, OPN contains an RGD sequence that 
binds to cell integrin receptors and is capable of promoting migration and proliferation of 
tumor cells [97,102,112]. Due to this property expression of OPN by tumor cells may 
play a role in tumor cell invasion and metastasis. Elevated expression of OPN found in 
metastatic lesions [103] and in cancer cells with high invasive properties [102] support 
the importance of OPN in tumor metastasis. Evidently, there are multiple mechanisms 
by which OPN could impact on the metastatic process. Through its adhesive properties 
OPN can induce changes in tumor cell gene expression including proteolytic enzymes, 
which in turn may lead to increased cell motility and invasion [102]. OPN also promotes 
angiogenesis, which is crucial for tumor growth and metastasis [93-95,108]. Consistent 
with these observations the current data, for the first time, show the association of 
plasma OPN with tumor progression and metastases in patients with RCC. 
 
4.2.1 Levels of osteopontin, bone markers, and enzymes 
 
OPN is one of the most abundant non-collagenous proteins in bone and plays an 
important role in bone remodeling [5,7]. In RCC, bone metastases are found in 30% of 
patients with metastases either alone or in combination with metastases in other 
locations [15-17]. In the current research design, the patients with distant metastases 
were classified according to those with bone and non-bone metastases, originally 
expecting that OPN could possibly be a marker for bone metastases in RCC as well. 
However, the results of the present study showed that neither plasma OPN nor the well-
known bone resorption and formation markers such as ICTP and bALP were able to 
differentiate between non-bone and bone distant metastases in RCC. As shown in 
Figure 12, compared to controls and RCC patients without metastases (N0 group) 
plasma OPN levels were significantly elevated in RCC patients with distant metastases 
regardless of the presence or absence of bone metastases (M1nb and M1b groups). In 
addition, also GGT and ALAT were rather ineffective markers to discriminate between 
RCC patients with and without metastases (Figure 12). Similar results had been 
reported previously in a large study involving six bone markers. In that study bone 
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markers were not sensitive enough to differentiate between RCC patients with bone and 
non-bone metastases [134]. 
As shown in Figure 12, plasma OPN appears to reflect tumor extension towards 
metastasis in RCC, since the median value (31 µg/L) in a group with local tumor is two 
times lower than in a group with regional lymph node metastases (66 µg/L) with the 
highest values being in the two groups with distant metastases (100 and 126 µg/L). This 
fact of significant elevation of plasma OPN values in metastatic RCC patients suggests 
its possible clinical application as a non-invasive marker to diagnose metastasis in RCC 
patients. Recent data on OPN tissue expression support the present results. OPN 
expression in tissue samples of organ-confined RCC was significantly lower compared 
to those invading beyond kidney [98]. However, in regard to plasma OPN, it should be 
noted that various cell types including immune, endothelial, smooth muscle and nerve 
cells secrete OPN [72,135]. Therefore, besides malignancy other pathological 
conditions such as inflammation, neurological disorders or cardiovascular diseases may 
also contribute to the elevation of OPN level in plasma [3,136]. This fact should also be 
taken into consideration when evaluating the results. Interestingly, OPN derived from 
malignant cells has structural properties different from those of host immune cells 
apparently due to post-translational modification [72,135]. Obviously, OPN derived from 
host cells mediates migration, proliferation, and survival of immune cells whereas OPN 
molecules synthesized by tumor cells are involved in tumor progression and metastasis. 
In support of this view OPN intensity in malignant cells was associated with tumor 
aggressiveness and the survival time of cancer patients [137]. 
 
4.2.2 Correlation between osteopontin, bone markers, and clinico-pathological data 
 
OPN concentrations correlated strongly with tumor stage (Table 9). Levels of 
OPN were significantly lower in RCC patients with tumor stage T1 compared to those 
with stage T2 or stages T3-4 with the medians 31, 82 and 116 µg/L, respectively (Table 
10). Correlation of plasma OPN with tumor stage was earlier reported in lung, liver, and 
bladder cancers [57-59]. Moreover, plasma OPN in RCC patients was associated with 
tumor grade (Table 9). RCC patients with tumor grades I-II had lower concentrations of 
OPN in plasma compared to those with grade III with the medians 46 vs. 116 µg/L 
(Table 10). This close correlation with clinico-pathological data clearly indicates that 
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plasma OPN is associated with tumor progression in RCC patients. Recent data on 
OPN protein expression in RCC tissue samples are consistent with the current results. 
In those studies OPN expression correlated with tumor stage and was significantly 
higher in tumor stages III-IV compared to that of I-II stages [47,98]. Significant 
difference of plasma OPN levels in different tumor stages also allows to distinguish 
RCC patients with stage I tumor from those with the advanced stages. In this respect, 
plasma OPN was more accurate with AUC of 0.84 compared to 0.75 of ICTP (Figure 14 
A, Table 14 A). On the other hand, when plasma OPN was examined in regard to the 
number of metastatic sites (one, two, and three or more), no differences in 
concentrations of OPN were observed between these groups (Table 11). In contrast to 
these results, plasma OPN in metastatic breast cancer patients appears to increase 
with the number of organs affected by metastasis reflecting the metastatic burden in 
these patients [56]. In the same study plasma OPN strongly (rs=0.81) correlated with 
tALP. Similar to that, correlation analysis in the present study revealed a close 
correlation of plasma OPN with the bone markers ICTP and bALP (Table 9). Correlation 
of OPN with these bone markers, which are known to reflect the extent of disease, 
suggests that OPN could also be related to the tumor extension. 
In relation to histological types clear cell RCC is the most frequent type with an 
incidence of 70% followed by the papillary and chromophobe types with 10% and 5% 
[21]. In accordance with these statistical data in the current study of 70 RCC patients 
with available histological data, 55 (79%) had clear cell type whereas 8 (11%) and 2 
(3%) of RCC patients presented with papillary and chromophobe types. 
Characterization of histological types in RCC is known to provide prognostic information 
for these patients. Patients with clear cell RCC tend to have better prognosis compared 
to those with papillary or chromophobe RCC [21]. However, in the current study levels 
of plasma OPN showed no association with different histological types of RCC (Table 
12). 
 
4.2.3 Diagnostic performance of osteopontin and bone markers 
 
As described previously in the current study and by other authors [37] ICTP is a 
reliable indicator of metastatic spread to bone in PCa patients. However, in RCC 
patients ICTP, a bone resorption marker, is ineffective in the diagnosis of bone 
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metastases (Figure 12) even though bone lesions in RCC are known to be osteolytic 
[18]. Since ICTP and OPN were elevated in both RCC groups with bone and non-bone 
distant metastases diagnostic performance of these markers was evaluated in relation 
to distant metastases. ROC analysis showed that OPN is more accurate compared to 
ICTP with the difference in AUC of 0.181 (P=0.018) (Figure 14). 
Plasma OPN compared to other markers was confirmed in a multivariate logistic 
regression model as the only significant variable related to the probability of distant 
metastasis in RCC patients (Table 13). Therefore, a combination of two significant 
variables as described in Chapter 3.1.3. in order to increase diagnostic accuracy was 
not possible. The results of multivariate logistic regression analysis indicated that 
plasma OPN in comparison with the other variables had the best potential to identify 
RCC patients with distant metastases (Table 13). 
 
4.2.4 Prognostic significance of osteopontin and bone markers 
 
In addition to the use of OPN as diagnostic marker, plasma OPN was examined 
with regard to its prognostic significance. Several studies examining other cancer types 
proved increased OPN values to be a significant prognostic factor for the overall 
survival [54,55,60]. Since diverse ELISAs have been employing different techniques, 
antibodies, and calibrators, a comparison of the OPN cutoffs defined in these different 
studies as prognostic decision level is less reasonable. In the case of OPN, that 
technical aspect may be more important than the cutoff defined using either the arbitrary 
or data-derived methods [138]. In the present study univariate Cox regression analyses 
confirmed the well-known prognostic significance of tumor stage and grade as well as 
the presence of metastases and proved the current study groups as appropriate for 
further analyses (Table 15). Plasma OPN retained significance as a predictor of death 
from RCC verified by the univariate Cox regression calculation (P=0.004) and 
demonstrated by the survival curves of Kaplan-Meier analysis (Figure 15). Patients with 
plasma OPN values below the cutoff of 90 percentile of the control group tended to 
have longer survival times compared to those with higher OPN values. In a multivariate 
Cox regression model with stepwise forward or backward elimination procedure 
increased OPN was proven to be an independent prognostic factor of survival 
probability in RCC patients in addition to the risk factor of metastasis (Table 15). Thus, 
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increased OPN values were associated with an increase in risk of death of 2.92. In 
patients with metastatic breast cancer OPN was recently shown to be the variable with 
the highest prognostic value for poor survival with a relative risk of 3.26 [55]. In addition, 
prognostic significance of OPN was also confirmed on a tissue level. The intensity of 
OPN protein expression in RCC tissue samples inversely correlated with the survival of 




Plasma OPN is an effective marker in the detection of bone metastases in PCa 
patients. Moreover, the combination of OPN with bALP significantly enhances 
diagnostic accuracy in relation to bone metastases. In RCC patients plasma OPN is 
useful in the diagnosis of distant bone and non-bone metastases and reflects tumor 
progression. In addition, evaluation of OPN in plasma has prognostic significance for 
both PCa and RCC patients. 
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5 Summary 
Osteopontin (OPN) is a glycoprotein, which is present in all body fluids including 
plasma. Due to the presence of arginine-glycine-aspartic acid sequence (RGD) in its 
structure OPN is capable of binding to cell integrin receptors and promoting adhesion, 
proliferation, and survival in various cell types including tumor cells. Its involvement in 
tumor progression and metastasis has been indicated in a number of studies. For 
example, tumor cells with high invasive properties or obtained from metastatic lesions 
show elevated OPN expression and, moreover, OPN expression in tissue correlates 
with tumor stage and size as well as survival of cancer patients. All these findings 
suggest that elevation of OPN levels in blood could also reflect tumor progression 
towards metastasis and poor prognosis for cancer patients. In addition, OPN is 
abundantly distributed in bone tissue and involved in the regulation of bone turnover. 
This indicates that OPN in plasma could also be a sensitive indicator of skeletal 
metastasis, since the latter alters finely balanced processes of bone turnover. The 
PubMed literature review has shown that reports on plasma OPN in prostate cancer 
(PCa) are very limited whereas in renal cell carcinoma (RCC) no studies have been 
done so far. Therefore, the aim of this study was to evaluate the clinical usefulness of 
plasma OPN in patients suffering from PCa and RCC. Diagnostic and prognostic 
significance of plasma OPN was compared with the established bone formation 
markers: N-terminal propeptide of type I procollagen (PINP), bone-specific alkaline 
phosphatase (bALP) and the bone resorption marker: cross-linked carboxyterminal 
telopeptide of type I collagen (ICTP). 
Prostate cancer. This study included 90 patients with PCa, 35 patients with 
benign prostatic hyperplasia (BPH) and 29 healthy men. Plasma OPN and bone 
markers were significantly elevated in PCa patients with bone metastases compared to 
those without bone metastases, BPH group, and controls (P<0.05 at least). OPN and 
bone markers were effective in the detection of bone metastases with AUC ranged from 
0.80 to 0.88 (all P<0.0001). There were no significant differences between ROC curves 
of OPN and bone markers. However, at the cutoff level of 95% sensitivity, specificity of 
OPN outperformed that of bALP and PINP (P=0.0266 and 0.0009, McNemar test). Only 
OPN and bALP in the multivariate binary logistic model retained significant predictive 
value in relation to bone metastasis in PCa patients (P=0.011 and 0.001). Combination 
of these two markers using logistic regression approach in order to enhance the 
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diagnostic accuracy in the detection of bone metastases led to a distinct increase in 
AUC up to 0.93 compared to OPN (AUC, 0.85; P=0.026) and bALP (AUC, 0.88; 
P=0.008). At the cutoff with 95% sensitivity, the specificity of OPN and bALP in 
combination amounted to 63% and was greater than that for OPN (31%) and bALP 
(11%). OPN correlated closely with the bone markers (rs=0.43-0.79, all P<0.05) and 
with tumor grade (rs=0.23, P<0.05). OPN and all bone markers were associated with 
survival (Kaplan-Meier, P<0.0001). PCa patients with high concentration of biochemical 
markers had shorter survival time than those with lower concentrations of biochemical 
markers. OPN and PINP were identified in multivariate Cox regression model as 
independent predictors of survival outcome in PCa patients. 
Renal cell carcinoma. This study included 80 patients with RCC and 52 controls. 
Compared to controls plasma OPN and ICTP were elevated in patients with distant 
bone and non-bone metastases (P<0.05 at least). Moreover, plasma OPN was also 
elevated in RCC patients with distant metastases compared to those with organ-
confined disease (P<0.05 at least). OPN and ICTP were examined in ROC analysis in 
relation to distant metastases. ROC curve of OPN (AUC, 0.89) was larger than that of 
ICTP (AUC, 0.71, P=0.018). At the cutoff with 95 % sensitivity, the specificity of OPN 
(57%) outperformed (McNemar test, P=0.0309) that of ICTP (25%). OPN correlated 
closely with the bone markers (rs=0.37-0.50, all P<0.05). Significant correlation was also 
observed between OPN and tumor stage (rs=0.50, P<0.01) and grade (rs=0.33, P<0.05). 
Levels of OPN and ICTP were associated with survival (Kaplan-Meier, P<0.0001). 
Patients with high concentrations of these two markers had shorter survival time than 
those with lower concentrations of OPN and ICTP. Logistic regression model 
determined OPN as a significant independent variable with predictive value related to 
distant metastasis in RCC patients (P=0.004). OPN was identified in Cox regression 
model as an independent factor related to the survival outcome in patients with RCC 
(P=0.041). 
In conclusion, plasma OPN is an effective marker in the detection of bone 
metastases in PCa patients. Moreover, combination of OPN with bALP significantly 
enhances diagnostic accuracy in relation to bone metastases. In RCC patients plasma 
OPN is useful in the diagnosis of distant bone and non-bone metastases and reflects 
tumor progression. In addition, evaluation of OPN in plasma has prognostic significance 
for both PCa and RCC patients. 
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Zusammenfassung 
Osteopontin (OPN) ist ein Glycoprotein, das in allen menschlichen Flüssigkeiten 
einschließlich Plasma vorkommt. Auf Grund der Arginin-Glycin-Asparaginsäure- 
Sequenz (RGD) in der Struktur des OPN-Proteins ist dieses fähig, sich an die Integrin-
Rezeptoren der Zellen zu binden. Dadurch werden Adhäsion, Proliferation und das 
Überleben von verschiedenen Zellen, auch Tumorzellen positiv beeinflusst. Die 
Bedeutung des OPN-Proteins hinsichtlich Tumorprogression und Metastasierung wurde 
in zahlreichen Studien bewiesen. In invasiven Tumorzellen oder Tumorzellen aus 
Metastasen fanden sich erhöhte Mengen von OPN. Die OPN-Expression im 
Tumorgewebe korreliert mit Tumorstadium und Tumorgröße sowie mit der 
Überlebenszeit der Patienten. Alle diese Ergebnisse deuten darauf hin, dass ein 
Anstieg von OPN im Plasma die Tumorprogression zur Metastasierung und damit eine 
schlechte Prognose für den Patienten anzeigt. Durch das reichliche Vorkommen von 
OPN im Knochen und seiner Bedeutung für Regulierung beim Knochenumsatz, könnte 
ein erhöhter OPN-Wert im Plasma ein sensitiver Indikator der Knochenmetastasierung 
sein. Eine eigene PubMed-Literaturrecherche ergab nur wenige Publikationen über das 
Verhalten des Plasma-OPN bei Patienten mit einem Prostatakarzinom (PCa). Bei 
Patienten mit einem Nierenzellkarzinom (RCC) war dies bisher kein Gegenstand von 
Untersuchungen. Deshalb war das Ziel der Studie, die klinische Aussagekraft von 
Plasma-OPN bei PCa- und RCC-Patienten zu ermitteln. Die diagnostische und 
prognostische Bedeutung von Plasma-OPN wurde mit Markern des Knochenaufbaus, 
dem N-terminalen Propeptid vom Typ I Prokollagen (PINP) und der 
knochenspezifischen alkalischen Phosphatase (bALP) sowie mit dem 
Knochenabbaumarker, dem quervernetzten, karboxyterminalen Telopeptid vom Typ I 
Prokollagen (ICTP), verglichen. 
Prostatakarzinom. Diese Studie umfasste 90 PCa-Patienten, 35 Patienten mit 
benigner Prostatahyperplasie (BPH) und 29 gesunde Männer. OPN und die 
Knochenmarker waren im Plasma von Patienten mit Knochen-Metastasen im Vergleich 
zu denen ohne Knochen-Metastasen, zu BPH-Patienten und Gesunden wesentlich 
erhöht (P<0.05 mindestens). Knochenmetastasen wurden bei den Patienten durch die 
Knochenszintigraphie sowie weitere Untersuchungen gesichert. OPN und 
Knochenmarker wiesen in der receiver operation characteristic-(ROC)-Analyse eine 
gute Diskrimination zwischen Patienten mit und ohne Knochenmetastasen auf. Die 
Flächen unter den ROC-Kurven (AUC) lagen zwischen 0.80 bis 0.88 (alle P-Werte 
<0.0001). Es gab keine entscheidenden Unterschiede zwischen den AUCs der ROC-
Kurven von OPN und Knochenmarkern. Jedoch war beim Diskriminationspunkt von 
95% Sensitivität die Spezifität von OPN höher als die Spezifität von bALP und PINP 
(P=0.026 und 0.0009, McNemar Test). OPN und bALP waren in der multivariaten 
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Auswertung mit der binären logistischen Regression signifikant unabhhängige 
Diskriminatoren in Bezug auf die Erfassung einer Knochenmetastasierung. Die 
Kombination dieser beiden Marker mit Hilfe der logistischer Regression ergab einen 
signifikant höheren AUC-Wert als für die Einzelmarker (AUC von 0.93 im Vergleich zu 
OPN mit AUC, 0.85; P=0.026 bzw. zu bALP mit AUC, 0.88; P=0.008). Beim 
Diskriminationspunkt von 95% Sensitivität erreichte die Kombination von OPN und 
bALP eine Spezifität von 63%. Diese war höher als die Spezifität von OPN (31%) und 
bALP (11%) für sich genommen. Es gab eine signifikant positive Korrelation von OPN 
zu den Knochenmarkern (rs=0.43-0.79, alle P-Werte <0.05) und zum Tumorgrad 
(rs=0.23, P<0.05). Die Konzentrationen von OPN und Knochenmarkern im Blut 
korrelierten negativ mit der Überlebenszeit der Patienten (Kaplan-Meier, P<0.0001). Je 
höher die Markerkonzentration, desto kürzer war die Überlebenszeit. OPN und PINP 
wurden mit Hilfe der multivariaten Cox-Regression als signifikante Indikatoren 
hinsichtlich Überlebenszeit von PCa-Patienten ermittelt. 
Nierenzellkarzinom. Diese Studie umfasste 80 RCC-Patienten mit lokal 
begrenztem Tumor, mit Lymphknotenmetastasen bzw. Fernmetastasen sowie 52 
gesunde Frauen und Männer als Kontrollgruppe. Im Vergleich zur Kontrollgruppe waren 
OPN und ICTP bei Patienten mit Fernmetastasen in Knochen und in anderen Organen 
(P<0.05 mindestens) erhöht. Erhöhte OPN-Werte wurden außerdem bei Patienten mit 
Fernmetastasen im Vergleich zu RCC-Patienten ohne Metastasen beobachtet (P<0.05 
mindestens). Die Beziehung von OPN und ICTP bei Patienten mit Fernmetastasen 
wurde weiter mit der ROC-Analyse untersucht. Der AUC-Wert für OPN (0.89) war 
größer als der für ICTP (AUC, 0.71, P=0.018). Beim Diskriminationspunkt von 95% 
Sensitivität betrug die Spezifität für OPN 57%, die für ICTP lediglich 25% (McNemar 
Test, P=0.0309). OPN zeigte signifikante Korrelationen mit Knochenmarkern (rs=0.37-
0.50, alle P Werte <0.05). Die OPN-Konzentration korrelierte mit dem Tumorstadium 
(rs=0.50, P<0.01) und Tumorgrad (rs=0.33, P<0.05). Konzentrationen von OPN und 
ICTP wurden außerdem mit der Überlebenszeit von RCC-Patienten assoziiert (Kaplan-
Meier, P<0.0001). In der multivariaten Cox-Regression erwies sich OPN als allein 
signifikanter Faktor hinsichtlich Überlebenszeit (P=0.041). 
Die wesentliche Schlussfolgerung aus den hier vorgestellten Untersuchungen 
besteht darin, dass OPN im Plasma bei Patienten mit Prostatakarzinom und 
Nierenzellkarzinom als Metastasierungs- und Prognosemarker hinsichtlich des 
Überlebens eingesetzt werden kann. Die Daten belegen, dass die Durchführung einer 
prospektiven multizentrischen Studie, die auch andere z.Z. diskutierte neue Marker wie 
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